

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### **APPLICATION NUMBER:**

**020931Orig1s001**

*Trade Name:* TIKOSYN

*Generic or Proper Name:* dofetilide

*Sponsor:* Pfizer Inc.

*Approval Date:* October 22, 2004

*Indication:* **Maintenance of Normal Sinus Rhythm (Delay in AF/AFL Recurrence)**

TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFL]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic.

In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see **CLINICAL STUDIES**).

**Conversion of Atrial Fibrillation/Flutter**

TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.

# CENTER FOR DRUG EVALUATION AND RESEARCH

020931Orig1s001

## CONTENTS

### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	
<b>Officer/Employee List</b>	
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Clinical Review(s)</b>	
<b>Product Quality Review(s)</b>	
<b>Non-Clinical Review(s)</b>	
<b>Statistical Review(s)</b>	
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Clinical Pharmacology Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**020931Orig1s001**

**APPROVAL LETTER**



NDA 20-931/S-001

Pfizer Inc.  
Attn: Robert Clark  
235 E. 42<sup>nd</sup> Street  
New York, NY 10017

Dear Mr. Clark:

Please refer to your supplemental new drug application dated March 19, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Tikosyn (dofetilide) 0.125, 0.25 and 0.5 mg Capsules.

We acknowledge receipt of your submissions dated March 24 and July 30, 2004.

This "Changes Being Effected in 30 days" supplemental new drug application provides for draft labeling revised as follows:

1. Throughout, "TIKOSYN<sup>TM</sup>" has been changed to "Tikosyn<sup>®</sup>."
2. Under **CONTRAINDICATIONS**, the following paragraph has been added after the second paragraph:

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with TIKOSYN is contraindicated (see **PRECAUTIONS, Drug-Drug Interactions**) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation.

3. The following sub-section has been moved from the **PRECAUTIONS** section to the **WARNINGS** section:

**Hypokalemia and Potassium-Depleting Diuretics**

Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics, increasing the potential for torsade de pointes. Potassium levels should be within the normal range prior to administration of TIKOSYN and maintained in the normal range during administration of TIKOSYN. (see **DOSAGE AND ADMINISTRATION**)

4. Under **WARNINGS/Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents**, the second sentence has been changed from:

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, and certain oral macrolides.

To:

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones.

5. Under **PRECAUTIONS/Information for Patients/**Medications and Supplements, the first sentence has been changed from:

Assessment of patients' medication history should include all over-the-counter, prescription and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see **CONTRAINDICATIONS**), trimethoprim alone or in combination with sulfamethoxazole (see **CONTRAINDICATIONS**), prochlorperazine (see **CONTRAINDICATIONS**), megestrol (see **CONTRAINDICATIONS**), ketoconazole (see **CONTRAINDICATIONS**), other cardiovascular drugs (especially verapamil - see **CONTRAINDICATIONS**), phenothiazines, and tricyclic antidepressants (see **WARNINGS**).

To:

Assessment of patients' medication history should include all over-the-counter, prescription and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see **CONTRAINDICATIONS**), trimethoprim alone or in combination with sulfamethoxazole (see **WARNINGS, CONTRAINDICATIONS**), prochlorperazine (see **WARNINGS, CONTRAINDICATIONS**), megestrol (see **WARNINGS, CONTRAINDICATIONS**), ketoconazole (see **WARNINGS, CONTRAINDICATIONS**), hydrochlorothiazide (alone or in combinations such as with triamterene) (see **CONTRAINDICATIONS**), other cardiovascular drugs (especially verapamil - see **CONTRAINDICATIONS**), phenothiazines, and tricyclic antidepressants (see **WARNINGS**).

6. Under **PRECAUTIONS/Drug-Drug Interactions**, “**WARNINGS**” has been added to the first parenthetical of the first sentence in the Cimetidine, Ketoconazole and Trimethoprim Alone or in Combination with Sulfamethoxazole sub-sections.
7. The following has been added to the **PRECAUTIONS/Drug-Drug Interactions** section:

Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: (see **CONTRAINDICATIONS**) Concomitant use of HCTZ alone or in combination with triamterene is contraindicated. HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and  $C_{max}$  by 21%. However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase). In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and  $C_{max}$  by 16%. However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase). The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium. In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).

8. Under **DOSAGE AND ADMINISTRATION**, the following has been added as the third bullet point:
 

Serum potassium should be maintained within the normal range before TIKOSYN treatment is initiated and should be maintained within the normal range while the patient remains on TIKOSYN therapy. (See **WARNINGS, Hypokalemia and Potassium Depleting Diuretics**) In clinical trials potassium levels were generally maintained above 3.6-4.0 mEq/L.
9. Under **DOSAGE AND ADMINISTRATION/Initiation of TIKOSYN Therapy/Step 2**, the term “body weight” has been changed to “actual body weight” in both creatinine clearance formulas (male and female).

10. The list number and issue date of the package insert have been updated.
11. In the Patient Information leaflet, under **Who should not take Tikosyn**/Do not take Tikosyn if you/are taking certain other medicines, including, the following has been added:

Hydrochlorothiazide alone or in combination with other medicines (such as ESIDRIX, EZIDE, HYDRODIURIL, HYDRO-PAR, MICROZIDE, or ORETIC)\*

12. In the Patient Information leaflet, under **Important points about Tikosyn**, the following has been added to the end of the sixth bullet point:

..., or hydrochlorothiazide alone or in combination with other medicines (such as ESIDRIX, EZIDE, HYDRODIURIL, HYDRO-PAR, MICROZIDE, or ORETIC)\*

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the submitted labeling.

The final printed labeling (FPL) must be identical to the labeling submitted on March 19, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-931/S-001." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact:

Mr. Russell Fortney  
Regulatory Health Project Manager  
(301) 594-5311

Sincerely,

*{See appended electronic signature page}*

Norman Stockbridge, M.D., Ph.D.  
Acting Director

Division of Cardio-Renal Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Norman Stockbridge  
10/22/04 04:21:01 PM

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**020931Orig1s001**

**LABELING**

**TIKOSYN<sup>®</sup>**


**(dofetilide)**

**Capsules**

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. For detailed instructions regarding dose selection, see **DOSAGE AND ADMINISTRATION**. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education; see **DOSAGE AND ADMINISTRATION**.

## DESCRIPTION

TIKOSYN<sup>®</sup> (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Its empirical formula is C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub> and it has a molecular weight of 441.6. The structural formula is



The chemical name for dofetilide is:

*N*-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide.

Dofetilide is a white to off-white powder. It is very slightly soluble in water and propan-2-ol and is soluble in 0.1M aqueous sodium hydroxide, acetone, and aqueous 0.1M hydrochloric acid.

TIKOSYN capsules contain the following inactive ingredients: microcrystalline cellulose, corn starch, colloidal silicon dioxide and magnesium stearate. TIKOSYN is supplied for oral administration in three dosage strengths: 125 mcg (0.125 mg) orange and white capsules, 250 mcg (0.25 mg) peach capsules, and 500 mcg (0.5 mg) peach and white capsules.

## CLINICAL PHARMACOLOGY

### Mechanism of Action

TIKOSYN (dofetilide) shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, I<sub>Kr</sub>. At concentrations covering several orders of magnitude, dofetilide blocks only I<sub>Kr</sub> with no relevant block of the other repolarizing potassium currents (e.g., I<sub>Ks</sub>, I<sub>K1</sub>). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

## Electrophysiology

TIKOSYN (dofetilide) increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. This effect, and the related increase in effective refractory period, is observed in the atria and ventricles in both resting and paced electrophysiology studies. The increase in QT interval observed on the surface ECG is a result of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles.

Dofetilide did not influence cardiac conduction velocity and sinus node function in a variety of studies in patients with or without structural heart disease. This is consistent with a lack of effect of dofetilide on the PR interval and QRS width in patients with pre-existing heart block and/or sick sinus syndrome.

In patients, dofetilide terminates induced re-entrant tachyarrhythmias (e.g., atrial fibrillation/flutter and ventricular tachycardia) and prevents their re-induction. TIKOSYN does not increase the electrical energy required to convert electrically induced ventricular fibrillation, and it significantly reduces the defibrillation threshold in patients with ventricular tachycardia and ventricular fibrillation undergoing implantation of a cardioverter-defibrillator device.

## Hemodynamic Effects

In hemodynamic studies, TIKOSYN had no effect on cardiac output, cardiac index, stroke volume index, or systemic vascular resistance in patients with ventricular tachycardia, mild to moderate congestive heart failure or angina, and either normal or low left ventricular ejection fraction. There was no evidence of a negative inotropic effect related to TIKOSYN therapy in patients with atrial fibrillation. There was no increase in heart failure in patients with significant left ventricular dysfunction (see **CLINICAL STUDIES, Safety in Patients with Structural Heart Disease, DIAMOND Studies**). In the overall clinical program, TIKOSYN did not affect blood pressure. Heart rate was decreased by 4–6 bpm in studies in patients.

## Pharmacokinetics, General

**Absorption and Distribution:** The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2–3 hours in the fasted state. Oral bioavailability is unaffected by food or antacid. The terminal half-life of TIKOSYN is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0. Plasma concentrations are dose proportional. Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment. Volume of distribution is 3 L/kg.

**Metabolism and Excretion:** Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. Renal elimination involves both glomerular filtration and active tubular secretion (via the cation transport system, a process that can be inhibited by cimetidine, trimethoprim, prochlorperazine, megestrol, ketoconazole and dolutegravir). *In vitro* studies with human liver microsomes show that dofetilide can be metabolized by CYP3A4, but it has a low affinity for this isoenzyme. Metabolites are formed by N-dealkylation and N-oxidation. There are no quantifiable metabolites circulating in plasma, but 5 metabolites have been identified in urine.

## Pharmacokinetics in Special Populations

**Renal Impairment:** In volunteers with varying degrees of renal impairment and patients with arrhythmias, the clearance of dofetilide decreases with decreasing creatinine clearance. As a result, and as seen in clinical studies, the half-life of dofetilide is longer in patients with lower creatinine clearances. **Because increase in QT interval and the risk of ventricular arrhythmias are directly related to plasma concentrations of dofetilide, dosage adjustment based on calculated creatinine clearance is critically important** (see **DOSAGE AND ADMINISTRATION**). Patients with severe renal impairment (creatinine clearance <20 mL/min) were not included in clinical or pharmacokinetic studies (see **CONTRAINDICATIONS**).

**Hepatic Impairment:** There was no clinically significant alteration in the pharmacokinetics of dofetilide in volunteers with mild to moderate hepatic impairment (Child-Pugh Class A and B) compared to age- and weight-matched healthy volunteers. Patients with severe hepatic impairment were not studied.

**Patients with Heart Disease:** Population pharmacokinetic analyses indicate that the plasma concentration of dofetilide in patients with supraventricular and ventricular arrhythmias, ischemic heart disease, or congestive heart failure are similar to those of healthy volunteers, after adjusting for renal function.

**Elderly:** After correction for renal function, clearance of dofetilide is not related to age.


**Women:** A population pharmacokinetic analysis showed that women have approximately 12–18% lower dofetilide oral clearances than men (14–22% greater plasma dofetilide levels), after correction for weight and creatinine clearance. In females, as in males, renal function was the single most important factor influencing dofetilide clearance. In normal female volunteers, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone) did not increase dofetilide exposure.

## Drug-Drug Interactions (see **PRECAUTIONS**)

### Dose-Response and Concentration Response for Increase in QT Interval

Increase in QT interval is directly related to dofetilide dose and plasma concentration. Figure 1 shows that the relationship in normal volunteers between dofetilide plasma concentrations and change in QTc is linear, with a positive slope of approximately 15–25 msec/(ng/mL) after the first dose and approximately 10–15 msec/(ng/mL) at Day 23 (reflecting a steady state of dosing). A linear relationship between mean QTc increase and dofetilide dose was also seen in patients with renal impairment, in patients with ischemic heart disease, and in patients with supraventricular and ventricular arrhythmias.


**Figure 1: Mean QTc-Concentration Relationship in Young Volunteers Over 24 Days**



Note: The range of dofetilide plasma concentrations achieved with the 500 mcg BID dose adjusted for creatinine clearance is 1–3.5 ng/mL.

The relationship between dose, efficacy, and the increase in QTc from baseline at steady state for the two randomized, placebo-controlled studies (described further below) is shown in Figure 2. The studies examined the effectiveness of TIKOSYN in conversion to sinus rhythm and maintenance of normal sinus rhythm after conversion in patients with atrial fibrillation/flutter of >1 week duration. As shown, both the probability of a patient's remaining in sinus rhythm at six months and the change in QTc from baseline at steady state of dosing increased in an approximately linear fashion with increasing dose of TIKOSYN. Note that in these studies, doses were modified by results of creatinine clearance measurement and in-hospital QTc prolongation.

**Figure 2: Relationship Between TIKOSYN Dose, QTc Increase and Maintenance of NSR**



Number of patients evaluated for maintenance of NSR: 503 TIKOSYN, 174 placebo.  
 Number of patients evaluated for QTc change: 478 TIKOSYN, 167 placebo.

## CLINICAL STUDIES

### Chronic Atrial Fibrillation and/or Atrial Flutter

Two randomized, parallel, double-blind, placebo-controlled, dose-response trials evaluated the ability of TIKOSYN 1) to convert patients with atrial fibrillation or atrial flutter (AF/AFI) of more than 1 week duration to normal sinus rhythm (NSR) and 2) to maintain NSR (delay time to recurrence of AF/AFI) after drug-induced or electrical cardioversion. A total of 996 patients with a one week to two year history of atrial fibrillation/atrial flutter were enrolled. Both studies randomized patients to placebo or to doses of TIKOSYN 125 mcg, 250 mcg, 500 mcg, or in one study a comparator drug, given twice a day (these doses were lowered based on calculated creatinine clearance and, in one of the studies, for QT interval or QTc). **All patients were started on therapy in a hospital where their ECG was monitored (see DOSAGE AND ADMINISTRATION).**

Patients were excluded from participation if they had had syncope within the past 6 months, AV block greater than first degree, MI or unstable angina within 1 month, cardiac surgery within 2 months, history of QT interval prolongation or polymorphic ventricular tachycardia associated with use of antiarrhythmic drugs, QT interval or QTc >440 msec, serum creatinine >2.5 mg/mL, significant diseases of other organ systems; used cimetidine; or used drugs known to prolong the QT interval.

Both studies enrolled mostly Caucasians (over 90%), males (over 70%), and patients  $\geq 65$  years of age (over 50%). Most (>90%) were NYHA Functional Class I or II. Approximately one-half had structural heart disease (including ischemic heart disease, cardiomyopathies, and valvular disease) and about one-half were hypertensive. A substantial proportion of patients were on concomitant therapy, including digoxin (over 60%), diuretics (over 20%), and ACE inhibitors (over 30%). About 90% were on anticoagulants.

Acute conversion rates are shown in Table 1 for randomized doses (doses were adjusted for calculated creatinine clearance and, in Study 1, for QT interval or QTc). Of patients who converted pharmacologically, approximately 70% converted within 24–36 hours.

**Table 1: Conversion of Atrial Fibrillation/Flutter to Normal Sinus Rhythm**

	TIKOSYN Dose			Placebo
	125 mcg BID	250 mcg BID	500 mcg BID	
Study 1	5/82(6%)	8/82(10%)	23/77(30%)	1/84(1%)
Study 2	8/135(6%)	14/133(11%)	38/129(29%)	2/137(1%)

Patients who did not convert to NSR with randomized therapy within 48–72 hours had electrical cardioversion. Those patients remaining in NSR after conversion in hospital were continued on randomized therapy as outpatients (maintenance period) for up to one year unless they experienced a recurrence of atrial fibrillation/atrial flutter or withdrew for other reasons.

Table 2 shows, by randomized dose, the percentage of patients at 6 and 12 months in both studies who remained on treatment in NSR and the percentage of patients who withdrew because of recurrence of AF/AFl or adverse events.

**Table 2: Patient Status at 6 and 12 Months Post Randomization**

	TIKOSYN Dose			Placebo
	125 mcg BID	250 mcg BID	500 mcg BID	
Study 1				
Randomized	82	82	77	84
Achieved NSR	60	61	61	68
6 months				
Still on treatment in NSR	38%	44%	52%	32%
D/C for recurrence	55%	49%	33%	63%
D/C for AEs	3%	3%	8%	4%
12 months				
Still on treatment in NSR	32%	26%	46%	22%
D/C for recurrence	58%	57%	36%	72%
D/C for AEs	7%	11%	8%	6%
Study 2				
Randomized	135	133	129	137
Achieved NSR	103	118	100	106
6 months				
Still on treatment in NSR	41%	49%	57%	22%
D/C for recurrence	48%	42%	27%	72%
D/C for AEs	9%	6%	10%	4%
12 months				
Still on treatment in NSR	25%	42%	49%	16%
D/C for recurrence	59%	47%	32%	76%
D/C for AEs	11%	6%	12%	5%

Note that columns do not add up to 100% due to discontinuations for “other” reasons.


Table 3 and Figures 3 and 4 show, by randomized dose, the effectiveness of TIKOSYN in maintaining NSR using Kaplan Meier analysis, which shows patients remaining on treatment.

**Table 3: P-Values and Median Time (days) to Recurrence of AF/AfI**

	TIKOSYN Dose			Placebo
	125 mcg BID	250 mcg BID	500 mcg BID	
Study 1				
p-value vs. placebo	P=0.21	P=0.10	P<0.001	
Median time to recurrence (days)	31	179	>365	27
Study 2				
p-value vs. placebo	P=0.006	P<0.001	P<0.001	
Median time to recurrence (days)	182	>365	>365	34


Median time to recurrence of AF/AfI could not be estimated accurately for the 250 mcg BID treatment group in Study 2 and the 500 mcg BID treatment groups in Studies 1 and 2 because TIKOSYN maintained >50% of patients (51%, 58%, and 66%, respectively) in NSR for the 12 months duration of the studies.

**Figure 3: Maintenance of Normal Sinus Rhythm, TIKOSYN Regimen vs. Placebo (Study 1)**



The point estimates of the probabilities of remaining in NSR at 6 and 12 months were 62% and 58%, respectively, for TIKOSYN 500 mcg BID; 50% and 37%, respectively, for TIKOSYN 250 mcg BID; and 37%, and 25%, respectively, for placebo.

**Figure 4: Maintenance of Normal Sinus Rhythm, TIKOSYN Regimen vs. Placebo (Study 2)**



The point estimates of the probabilities of remaining in NSR at 6 and 12 months were 71% and 66%, respectively, for TIKOSYN 500 mcg BID; 56% and 51%, respectively, for TIKOSYN 250 mcg BID; and 26% and 21%, respectively, for placebo.

In both studies, TIKOSYN resulted in a dose-related increase in the number of patients maintained in NSR at all time periods and delayed the time of recurrence of sustained AF. Data pooled from both studies show that there is a positive relationship between the probability of staying in NSR, TIKOSYN dose, and increase in QTc (see Figure 2 in **CLINICAL PHARMACOLOGY, Dose-Response and Concentration Response for Increase in QT Interval**).

Analysis of pooled data for patients randomized to a TIKOSYN dose of 500 mcg twice daily showed that maintenance of NSR was similar in both males and females, in both patients aged <65 years and patients ≥65 years of age, and in both patients with atrial flutter as a primary diagnosis and those with a primary diagnosis of atrial fibrillation.

During the period of in-hospital initiation of dosing, 23% of patients in Studies 1 and 2 had their dose adjusted downward on the basis of their calculated creatinine clearance, and 3% had their dose down-titrated due to increased QT interval or QTc. Increased QT interval or QTc led to discontinuation of therapy in 3% of patients.

#### **Safety in Patients with Structural Heart Disease: DIAMOND Studies (The Danish Investigations of Arrhythmia and Mortality on Dofetilide)**

The two DIAMOND studies were 3-year trials comparing the effects of TIKOSYN and placebo on mortality and morbidity in patients with impaired left ventricular function (ejection fraction ≤ 35%). Patients were treated for at least one year. One study was in patients with moderate to severe (60% NYHA Class III or IV) congestive heart failure (DIAMOND CHF) and the other was in patients with recent myocardial infarction (DIAMOND MI) (of whom 40% had NYHA

Class III or IV heart failure). Both groups were at relatively high risk of sudden death. The DIAMOND trials were intended to determine whether TIKOSYN could reduce that risk. The trials did not demonstrate a reduction in mortality; however, they provide reassurance that, when initiated carefully, in a hospital or equivalent setting, TIKOSYN did not increase mortality in patients with structural heart disease, an important finding because other antiarrhythmics [notably the Class IC antiarrhythmics studied in the Cardiac Arrhythmia Suppression Trial (CAST) and a pure Class III antiarrhythmic, d-sotalol (SWORD)] have increased mortality in post-infarction populations. The DIAMOND trials therefore provide evidence of a method of safe use of TIKOSYN in a population susceptible to ventricular arrhythmias. In addition, the subset of patients with AF in the DIAMOND trials provide further evidence of safety in a population of patients with structural heart disease accompanying the AF. Note, however, that this AF population was given a lower (250 mcg BID) dose (see **CLINICAL STUDIES, DIAMOND Patients with Atrial Fibrillation**).

In both DIAMOND studies, patients were randomized to 500 mcg BID of TIKOSYN, but this was reduced to 250 mcg BID if calculated creatinine clearance was 40–60 mL/min, if patients had AF, or if QT interval prolongation (>550 msec or >20% increase from baseline) occurred after dosing. Dose reductions for reduced calculated creatinine clearance occurred in 47% and 45% of DIAMOND CHF and MI patients, respectively. Dose reductions for increased QT interval or QTc occurred in 5% and 7% of DIAMOND CHF and MI patients, respectively. Increased QT interval or QTc (>550 msec or >20% increase from baseline) resulted in discontinuation of 1.8% of patients in DIAMOND CHF and 2.5% of patients in DIAMOND MI.

**In the DIAMOND studies, all patients were hospitalized for at least 3 days after treatment was initiated and monitored by telemetry.** Patients with QTc greater than 460 msec, second or third degree AV block (unless with pacemaker), resting heart rate <50 bpm, or prior history of polymorphic ventricular tachycardia were excluded.

DIAMOND CHF studied 1518 patients hospitalized with severe CHF who had confirmed impaired left ventricular function (ejection fraction  $\leq$ 35%). Patients received a median duration of therapy of greater than one year. There were 311 deaths from all causes in patients randomized to TIKOSYN (n=762) and 317 deaths in patients randomized to placebo (n=756). The probability of survival at one year was 73% (95% CI: 70% – 76%) in the TIKOSYN group and 72% (95% CI: 69% – 75%) in the placebo group. Similar results were seen for cardiac deaths and arrhythmic deaths. Torsade de Pointes occurred in 25/762 patients (3.3%) receiving TIKOSYN. The majority of cases (76%) occurred within the first 3 days of dosing. In all, 437/762 (57%) of patients on TIKOSYN and 459/756 (61%) on placebo required hospitalization. Of these, 229/762 (30%) of patients on TIKOSYN and 290/756 (38%) on placebo required hospitalization because of worsening heart failure.

DIAMOND MI studied 1510 patients hospitalized with recent myocardial infarction (2–7 days) who had confirmed impaired left ventricular function (ejection fraction  $\leq$ 35%). Patients received a median duration of therapy of greater than one year. There were 230 deaths in patients randomized to TIKOSYN (n=749) and 243 deaths in patients randomized to placebo (n=761). The probability of survival at one year was 79% (95% CI: 76% – 82%) in the TIKOSYN group and 77% (95% CI: 74% – 80%) in the placebo group. Cardiac and arrhythmic mortality showed a similar result. Torsade de Pointes occurred in 7/749 patients (0.9%) receiving TIKOSYN. Of these, 4 cases occurred within the first 3 days of dosing and 3 cases occurred between Day 4 and the conclusion of the study. In all, 371/749 (50%) of patients on TIKOSYN and 419/761 (55%)

on placebo required hospitalization. Of these, 200/749 (27%) of patients on TIKOSYN and 205/761 (27%) on placebo required hospitalization because of worsening heart failure.

DIAMOND Patients with Atrial Fibrillation (the DIAMOND AF subpopulation). There were 506 patients in the two DIAMOND studies who had atrial fibrillation (AF) at entry to the studies (249 randomized to TIKOSYN and 257 randomized to placebo). DIAMOND AF patients randomized to TIKOSYN received 250 mcg BID; 65% of these patients had impaired renal function, so that 250 mcg BID represents the dose they would have received in the AF trials, which would give drug exposure similar to a person with normal renal function given 500 mcg BID. In the DIAMOND AF subpopulation, there were 111 deaths (45%) in the 249 patients in the TIKOSYN group and 116 deaths (45%) in the 257 patients in the placebo group. Hospital readmission rates for any reason were 125/249 or 50% on TIKOSYN and 156/257 or 61% for placebo. Of these, readmission rates for worsening heart failure were 73/249 or 29% on TIKOSYN and 102/257 or 40% for placebo.

Of the 506 patients in the DIAMOND studies who had atrial fibrillation or flutter at baseline, 12% of patients in the TIKOSYN group and 2% of patients in the placebo group had converted to normal sinus rhythm after one month. In those patients converted to normal sinus rhythm, 79% of the TIKOSYN group and 42% of the placebo group remained in normal sinus rhythm for one year.

In the DIAMOND studies, although Torsade de Pointes occurred more frequently in the TIKOSYN-treated patients (see **ADVERSE REACTIONS**), TIKOSYN, given with an initial 3-day hospitalization and with dose modified for reduced creatinine clearance and increased QT interval, was not associated with an excess risk of mortality in these populations with structural heart disease in the individual studies or in an analysis of the combined studies. The presence of atrial fibrillation did not affect outcome.

## INDICATIONS AND USAGE

### **Maintenance of Normal Sinus Rhythm (Delay in AF/AFI Recurrence)**

TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFI]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic.

In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see **CLINICAL STUDIES**).

### **Conversion of Atrial Fibrillation/Flutter**

TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.

## CONTRAINDICATIONS

TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes. TIKOSYN should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). TIKOSYN is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min).

The concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with TIKOSYN is contraindicated (see **WARNINGS and PRECAUTIONS, Drug-Drug Interactions**), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. In addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on TIKOSYN.

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with TIKOSYN is contraindicated (see **PRECAUTIONS, Drug-Drug Interactions**) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation.

TIKOSYN is also contraindicated in patients with a known hypersensitivity to the drug.

## WARNINGS

**Ventricular Arrhythmia: TIKOSYN (dofetilide) can cause serious ventricular arrhythmias, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to dofetilide plasma concentration. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval.**

**Treatment with dofetilide must therefore be started only in patients placed for a minimum of three days in a facility that can provide electrocardiographic monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Calculation of the creatinine clearance for all patients must precede administration of the first dose of dofetilide. For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION.**

The risk of dofetilide induced ventricular arrhythmia was assessed in three ways in clinical studies: 1) by description of the QT interval and its relation to the dose and plasma concentration of dofetilide; 2) by observing the frequency of TdP in TIKOSYN-treated patients according to dose; 3) by observing the overall mortality rate in patients with atrial fibrillation and in patients with structural heart disease.

**Relation of QT Interval to Dose: The QT interval increases linearly with increasing TIKOSYN dose (see Figures 1 and 2 in CLINICAL PHARMACOLOGY and Dose-Response and Concentration Response for Increase in QT Interval).**

Frequency of Torsade de Pointes: In the supraventricular arrhythmia population (patients with AF and other supraventricular arrhythmias), the overall incidence of Torsade de Pointes was 0.8%. The frequency of TdP by dose is shown in Table 4. There were no cases of TdP on placebo.

**Table 4: Summary of Torsade de Pointes in Patients Randomized to Dofetilide by Dose; Patients with Supraventricular Arrhythmias**

	TIKOSYN Dose				
	<250 mcg BID	250 mcg BID	>250–500 mcg BID	>500 mcg BID	All Doses
Number of Patients	217	388	703	38	1346
Torsade de Pointes	0	1 (0.3%)	6 (0.9%)	4 (10.5%)	11 (0.8%)

As shown in Table 5, the rate of TdP was reduced when patients were dosed according to their renal function (see **CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations, Renal Impairment and DOSAGE AND ADMINISTRATION**).

**Table 5: Incidence of Torsade de Pointes Before and After Introduction of Dosing According to Renal Function**

Population:	Total	Before	After
	n/N %	n/N %	n/N %
Supraventricular Arrhythmias	11/1346 (0.8%)	6/193 (3.1%)	5/1153 (0.4%)
DIAMOND CHF	25/762 (3.3%)	7/148 (4.7%)	18/614 (2.9%)
DIAMOND MI	7/749 (0.9%)	3/101 (3.0%)	4/648 (0.6%)
DIAMOND AF	4/249 (1.6%)	0/43 (0%)	4/206 (1.9%)

The majority of the episodes of TdP occurred within the first three days of TIKOSYN therapy (10/11 events in the studies of patients with supraventricular arrhythmias; 19/25 and 4/7 events in DIAMOND CHF and DIAMOND MI, respectively; 2/4 events in the DIAMOND AF subpopulation).

**Mortality:** In a pooled survival analysis of patients in the supraventricular arrhythmia population (low prevalence of structural heart disease), deaths occurred in 0.9% (12/1346) of patients receiving TIKOSYN and 0.4% (3/677) in the placebo group. Adjusted for duration of therapy, primary diagnosis, age, gender, and prevalence of structural heart disease, the point estimate of the hazard ratio for the pooled studies (TIKOSYN/placebo) was 1.1 (95% CI: 0.3, 4.3). The DIAMOND CHF and MI trials examined mortality in patients with structural heart disease (ejection fraction  $\leq 35\%$ ). In these large, double-blind studies, deaths occurred in 36% (541/1511) of TIKOSYN patients and 37% (560/1517) of placebo patients. In an analysis of 506 DIAMOND patients with atrial fibrillation/flutter at baseline, one year mortality on TIKOSYN was 31% vs. 32% on placebo (see **CLINICAL STUDIES**).

Because of the small number of events, an excess mortality due to TIKOSYN cannot be ruled out with confidence in the pooled survival analysis of placebo-controlled trials in patients with supraventricular arrhythmias. However, it is reassuring that in two large placebo-controlled mortality studies in patients with significant heart disease (DIAMOND CHF/MI), there were no more deaths in TIKOSYN-treated patients than in patients given placebo (see **CLINICAL STUDIES**).

### **Drug-Drug Interactions (see CONTRAINDICATIONS)**

Because there is a linear relationship between dofetilide plasma concentration and QTc, concomitant drugs that interfere with the metabolism or renal elimination of dofetilide may

increase the risk of arrhythmia (Torsade de Pointes). TIKOSYN is metabolized to a small degree by the CYP3A4 isoenzyme of the cytochrome P450 system and an inhibitor of this system could increase systemic dofetilide exposure. More important, dofetilide is eliminated by cationic renal secretion, and three inhibitors of this process have been shown to increase systemic dofetilide exposure. The magnitude of the effect on renal elimination by cimetidine, trimethoprim, and ketoconazole (all contraindicated concomitant uses with dofetilide) suggests that all renal cation transport inhibitors should be contraindicated.

### **Hypokalemia and Potassium-Depleting Diuretics**

Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics, increasing the potential for Torsade de Pointes. Potassium levels should be within the normal range prior to administration of TIKOSYN and maintained in the normal range during administration of TIKOSYN (see **DOSAGE AND ADMINISTRATION**).

### **Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents**

The use of TIKOSYN in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones. Class I or Class III antiarrhythmic agents should be withheld for at least three half-lives prior to dosing with TIKOSYN. In clinical trials, TIKOSYN was administered to patients previously treated with oral amiodarone only if serum amiodarone levels were below 0.3 mg/L or amiodarone had been withdrawn for at least three months.

## **PRECAUTIONS**

### **Renal Impairment**

The overall systemic clearance of dofetilide is decreased and plasma concentration increased with decreasing creatinine clearance. The dose of TIKOSYN must be adjusted based on creatinine clearance (see **DOSAGE AND ADMINISTRATION**). Patients undergoing dialysis were not included in clinical studies, and appropriate dosing recommendations for these patients are unknown. There is no information about the effectiveness of hemodialysis in removing dofetilide from plasma.

### **Hepatic Impairment**

After adjustment for creatinine clearance, no additional dose adjustment is required for patients with mild or moderate hepatic impairment. Patients with severe hepatic impairment have not been studied. TIKOSYN should be used with particular caution in these patients.

### **Cardiac Conduction Disturbances**

Animal and human studies have not shown any adverse effects of dofetilide on conduction velocity. No effect on AV nodal conduction following TIKOSYN treatment was noted in normal volunteers and in patients with 1<sup>st</sup> degree heart block. Patients with sick sinus syndrome or with 2<sup>nd</sup> or 3<sup>rd</sup> degree heart block were not included in the Phase 3 clinical trials unless a functioning pacemaker was present. TIKOSYN has been used safely in conjunction with pacemakers (53 patients in DIAMOND studies, 136 in trials in patients with ventricular and supraventricular arrhythmias).

## Information for Patients

Please refer patient to the Medication Guide.

**Prior to initiation of TIKOSYN therapy, the patient should be advised to read the Medication Guide and reread it each time therapy is renewed in case the patient's status has changed. The patient should be fully instructed on the need for compliance with the recommended dosing of TIKOSYN and the potential for drug interactions, and the need for periodic monitoring of QTc and renal function to minimize the risk of serious abnormal rhythms.**

**Medications and Supplements:** Assessment of patients' medication history should include all over-the-counter, prescription, and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see **CONTRAINDICATIONS**), trimethoprim alone or in combination with sulfamethoxazole (see **WARNINGS, CONTRAINDICATIONS**), prochlorperazine (see **WARNINGS, CONTRAINDICATIONS**), megestrol (see **WARNINGS, CONTRAINDICATIONS**), ketoconazole (see **WARNINGS, CONTRAINDICATIONS**), dolutegravir (see **CONTRAINDICATIONS**), hydrochlorothiazide (alone or in combinations such as with triamterene) (see **CONTRAINDICATIONS**), other cardiovascular drugs (especially verapamil – see **CONTRAINDICATIONS**), phenothiazines, and tricyclic antidepressants (see **WARNINGS**). If a patient is taking TIKOSYN and requires anti-ulcer therapy, omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) should be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetics of TIKOSYN. Patients should be instructed to notify their health care providers of any change in over-the-counter, prescription, or supplement use. If a patient is hospitalized or is prescribed a new medication for any condition, the patient must inform the health care provider of ongoing TIKOSYN therapy. Patients should also check with their health care provider and/or pharmacist prior to taking a new over-the-counter preparation.

**Electrolyte Imbalance:** If patients experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, or vomiting or loss of appetite or thirst, these conditions should immediately be reported to their health care provider.

**Dosing Schedule:** Patients should be instructed NOT to double the next dose if a dose is missed. The next dose should be taken at the usual time.

## Drug/Laboratory Test Interactions

None known.

## Drug-Drug Interactions

**Cimetidine:** (see **WARNINGS, CONTRAINDICATIONS**) Concomitant use of cimetidine is contraindicated. Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%. Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose). No studies have been conducted at intermediate doses of cimetidine. If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.

**Verapamil:** (see **CONTRAINDICATIONS**) Concomitant use of verapamil is contraindicated. Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased. In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of Torsade de Pointes.

**Ketoconazole:** (see **WARNINGS, CONTRAINDICATIONS**) Concomitant use of ketoconazole is contraindicated. Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide  $C_{max}$  by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.

**Trimethoprim Alone or in Combination with Sulfamethoxazole:** (see **WARNINGS, CONTRAINDICATIONS**) Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated. Trimethoprim 160 mg in combination with 800 mg sulfamethoxazole co-administered BID with TIKOSYN (500 mcg BID) for 4 days has been shown to increase dofetilide AUC by 103% and  $C_{max}$  by 93%.

**Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene:** (see **CONTRAINDICATIONS**) Concomitant use of HCTZ alone or in combination with triamterene is contraindicated. HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and  $C_{max}$  by 21%. However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase). In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and  $C_{max}$  by 16%. However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (maximum QTc increase). The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium. In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI: 0.376, 1.230).

## Potential Drug Interactions

Dofetilide is eliminated in the kidney by cationic secretion. Inhibitors of renal cationic secretion are contraindicated with TIKOSYN. In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.

Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system. Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure. Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously co-administered with

TIKOSYN as they can potentially increase dofetilide levels. Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9, CYP2D6) and is not expected to increase levels of drugs metabolized by CYP3A4.

### **Other Drug Interaction Information**

**Digoxin:** Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin. In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of Torsade de Pointes. It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin; structural heart disease is a known risk factor for arrhythmia. No increase in mortality was observed in patients taking digoxin as concomitant medication.

**Other Drugs:** In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of TIKOSYN. In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.

Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide. Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs. Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%. The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Dofetilide had no genotoxic effects, with or without metabolic activation, based on the bacterial mutation assay and tests of cytogenetic aberrations *in vivo* in mouse bone marrow and *in vitro* in human lymphocytes. Rats and mice treated with dofetilide in the diet for two years showed no evidence of an increased incidence of tumors compared to controls. The highest dofetilide dose administered for 24 months was 10 mg/kg/day to rats and 20 mg/kg/day to mice. Mean dofetilide AUCs<sub>(0-24hr)</sub> at these doses were about 26 and 10 times, respectively, the maximum likely human AUC.

There was no effect on mating or fertility when dofetilide was administered to male and female rats at doses as high as 1.0 mg/kg/day, a dose that would be expected to provide a mean dofetilide AUC<sub>(0-24hr)</sub> about 3 times the maximum likely human AUC. Increased incidences of testicular atrophy and epididymal oligospermia and a reduction in testicular weight were, however, observed in other studies in rats. Reduced testicular weight and increased incidence of testicular atrophy were also consistent findings in dogs and mice. The no effect doses for these findings in chronic administration studies in these 3 species (3, 0.1, and 6 mg/kg/day) were

associated with mean dofetilide AUCs that were about 4, 1.3, and 3 times the maximum likely human AUC, respectively.

### **Pregnancy Category C**

Dofetilide has been shown to adversely affect *in utero* growth and survival of rats and mice when orally administered during organogenesis at doses of 2 or more mg/kg/day. Other than an increased incidence of non-ossified 5<sup>th</sup> metacarpal, and the occurrence of hydroureter and hydronephroses at doses as low as 1 mg/kg/day in the rat, structural anomalies associated with drug treatment were not observed in either species at doses below 2 mg/kg/day. The clearest drug-effect associations were for sternbral and vertebral anomalies in both species; cleft palate, adactyly, levocardia, dilation of cerebral ventricles, hydroureter, hydronephroses, and unossified metacarpal in the rat; and increased incidence of unossified calcaneum in the mouse. The “no observed adverse effect dose” in both species was 0.5 mg/kg/day. The mean dofetilide AUCs<sub>(0-24hr)</sub> at this dose in the rat and mouse are estimated to be about equal to the maximum likely human AUC and about half the likely human AUC, respectively. There are no adequate and well controlled studies in pregnant women. Therefore, dofetilide should only be administered to pregnant women where the benefit to the patient justifies the potential risk to the fetus.

### **Nursing Mothers**

There is no information on the presence of dofetilide in breast milk. Patients should be advised not to breast-feed an infant if they are taking TIKOSYN.

### **Geriatric Use**

Of the total number of patients in clinical studies of TIKOSYN, 46% were 65 to 89 years old. No overall differences in safety, effect on QTc, or effectiveness were observed between elderly and younger patients. Because elderly patients are more likely to have decreased renal function with a reduced creatinine clearance, care must be taken in dose selection (see **DOSAGE AND ADMINISTRATION**).

### **Use in Women**

Female patients constituted 32% of the patients in the placebo-controlled trials of TIKOSYN. As with other drugs that cause Torsade de Pointes, TIKOSYN was associated with a greater risk of Torsade de Pointes in female patients than in male patients. During the TIKOSYN clinical development program, the risk of Torsade de Pointes in females was approximately 3 times the risk in males. Unlike Torsade de Pointes, the incidence of other ventricular arrhythmias was similar in female patients receiving TIKOSYN and patients receiving placebo. Although no study specifically investigated this risk, in post-hoc analyses, no increased mortality was observed in females on TIKOSYN compared to females on placebo.

### **Pediatric Use**

The safety and effectiveness of TIKOSYN in children (<18 years old) has not been established.

## **ADVERSE REACTIONS**

The TIKOSYN clinical program involved approximately 8,600 patients in 130 clinical studies of normal volunteers and patients with supraventricular and ventricular arrhythmias. TIKOSYN was administered to 5,194 patients, including two large, placebo-controlled mortality trials (DIAMOND CHF and DIAMOND MI) in which 1,511 patients received TIKOSYN for up to three years.

In the following section, adverse reaction data for cardiac arrhythmias and non-cardiac adverse reactions are presented separately for patients included in the supraventricular arrhythmia development program and for patients included in the DIAMOND CHF and MI mortality trials (see **CLINICAL STUDIES, Safety in Patients with Structural Heart Disease, DIAMOND Studies**, for a description of these trials).

In studies of patients with supraventricular arrhythmias, a total of 1,346 and 677 patients were exposed to TIKOSYN and placebo for 551 and 207 patient years, respectively. A total of 8.7% of patients in the dofetilide groups were discontinued from clinical trials due to adverse events compared to 8.0% in the placebo groups. The most frequent reason for discontinuation (>1%) was ventricular tachycardia (2.0% on dofetilide vs. 1.3% on placebo). The most frequent adverse events were headache, chest pain, and dizziness.

**Serious Arrhythmias and Conduction Disturbances:** Torsade de Pointes is the only arrhythmia that showed a dose-response relationship to TIKOSYN treatment. It did not occur in placebo treated patients. The incidence of Torsade de Pointes in patients with supraventricular arrhythmias was 0.8% (11/1346) (see **WARNINGS**). The incidence of Torsade de Pointes in patients who were dosed according to the recommended dosing regimen (see **DOSAGE AND ADMINISTRATION**) was 0.8% (4/525). Table 6 shows the frequency by randomized dose of serious arrhythmias and conduction disturbances reported as adverse events in patients with supraventricular arrhythmias.

**Table 6: Incidence of Serious Arrhythmias and Conduction Disturbances in Patients with Supraventricular Arrhythmias**

Arrhythmia event:	TIKOSYN Dose				Placebo N=677
	<250 mcg BID N=217	250 mcg BID N=388	>250–500 mcg BID N=703	>500 mcg BID N=38	
Ventricular arrhythmias* ^	3.7%	2.6%	3.4%	15.8%	2.7%
Ventricular fibrillation	0	0.3%	0.4%	2.6%	0.1%
Ventricular tachycardia^	3.7%	2.6%	3.3%	13.2%	2.5%
Torsade de Pointes	0	0.3%	0.9%	10.5%	0
Various forms of block					
AV block	0.9%	1.5%	0.4%	0	0.3%
Bundle branch block	0	0.5%	0.1%	0	0.1%
Heart block	0	0.5%	0.1%	0	0.1%

\* Patients with more than one arrhythmia are counted only once in this category.

^ Ventricular arrhythmias and ventricular tachycardia include all cases of Torsade de Pointes.

In the DIAMOND trials, a total of 1,511 patients were exposed to TIKOSYN for 1757 patient years. The incidence of Torsade de Pointes was 3.3% in CHF patients and 0.9% in patients with a recent MI.

Table 7 shows the incidence of serious arrhythmias and conduction disturbances reported as adverse events in the DIAMOND subpopulation that had AF at entry to these trials.

**Table 7: Incidence of Serious Arrhythmias and Conduction Disturbances in Patients with AF at Entry to the DIAMOND Studies**

	TIKOSYN	Placebo
	N=249	N=257
Ventricular arrhythmias* ^	14.5%	13.6%
Ventricular fibrillation	4.8%	3.1%
Ventricular tachycardia^	12.4%	11.3%
Torsade de Pointes	1.6%	0
Various forms of block		
AV block	0.8%	2.7%
(Left) bundle branch block	0	0.4%
Heart block	1.2%	0.8%

\* Patients with more than one arrhythmia are counted only once in this category.

^ Ventricular arrhythmias and ventricular tachycardia include all cases of Torsade de Pointes.

**Other Adverse Reactions:** Table 8 presents other adverse events reported with a frequency of >2% on TIKOSYN and reported numerically more frequently on TIKOSYN than on placebo in the studies of patients with supraventricular arrhythmias.

**Table 8: Frequency of Adverse Events Occurring at >2% on TIKOSYN, and Numerically More Frequently on TIKOSYN than Placebo in Patients with Supraventricular Arrhythmias**

Adverse Event	TIKOSYN	Placebo
	%	%
headache	11	9
chest pain	10	7
dizziness	8	6
respiratory tract infection	7	5
dyspnea	6	5
nausea	5	4
flu syndrome	4	2
insomnia	4	3
accidental injury	3	1
back pain	3	2
procedure (medical/surgical/health service)	3	2
diarrhea	3	2
rash	3	2
abdominal pain	3	2

Adverse events reported at a rate >2% but no more frequently on TIKOSYN than on placebo were: angina pectoris, anxiety, arthralgia, asthenia, atrial fibrillation, complications (application, injection, incision, insertion, or device), hypertension, pain, palpitation, peripheral edema, supraventricular tachycardia, sweating, urinary tract infection, ventricular tachycardia.

The following adverse events have been reported with a frequency of ≤2% and numerically more frequently with TIKOSYN than placebo in patients with supraventricular arrhythmias: angioedema, bradycardia, cerebral ischemia, cerebrovascular accident, edema, facial paralysis,

flaccid paralysis, heart arrest, increased cough, liver damage, migraine, myocardial infarct, paralysis, paresthesia, sudden death, and syncope.

The incidences of clinically significant laboratory test abnormalities in patients with supraventricular arrhythmias were similar for patients on TIKOSYN and those on placebo. No clinically relevant effects were noted in serum alkaline phosphatase, serum GGT, LDH, AST, ALT, total bilirubin, total protein, blood urea nitrogen, creatinine, serum electrolytes (calcium, chloride, glucose, magnesium, potassium, sodium), or creatine kinase. Similarly, no clinically relevant effects were observed in hematologic parameters.

In the DIAMOND population, adverse events other than those related to the post-infarction and heart failure patient population were generally similar to those seen in the supraventricular arrhythmia groups.

## OVERDOSAGE

There is no known antidote to TIKOSYN; treatment of overdose should therefore be symptomatic and supportive. The most prominent manifestation of overdose is likely to be excessive prolongation of the QT interval.

In cases of overdose, cardiac monitoring should be initiated. Charcoal slurry may be given soon after overdosing but has been useful only when given within 15 minutes of TIKOSYN administration. Treatment of Torsade de Pointes or overdose may include administration of isoproterenol infusion, with or without cardiac pacing. Administration of intravenous magnesium sulfate may be effective in the management of Torsade de Pointes. Close medical monitoring and supervision should continue until the QT interval returns to normal levels.

Isoproterenol infusion into anesthetized dogs with cardiac pacing rapidly attenuates the dofetilide-induced prolongation of atrial and ventricular effective refractory periods in a dose-dependent manner. Magnesium sulfate, administered prophylactically either intravenously or orally in a dog model, was effective in the prevention of dofetilide-induced Torsade de Pointes ventricular tachycardia. Similarly, in man, intravenous magnesium sulfate may terminate Torsade de Pointes, irrespective of cause.

TIKOSYN overdose was rare in clinical studies; there were two reported cases of TIKOSYN overdose in the oral clinical program. One patient received very high multiples of the recommended dose (28 capsules), was treated with gastric aspiration 30 minutes later, and experienced no events. One patient inadvertently received two 500 mcg doses one hour apart and experienced ventricular fibrillation and cardiac arrest 2 hours after the second dose.

In the supraventricular arrhythmia population, only 38 patients received doses greater than 500 mcg BID, all of whom received 750 mcg BID irrespective of creatinine clearance. In this very small patient population, the incidence of Torsade de Pointes was 10.5% (4/38 patients), and the incidence of new ventricular fibrillation was 2.6% (1/38 patients).

## DOSAGE AND ADMINISTRATION

- Therapy with TIKOSYN must be initiated (and, if necessary, re-initiated) in a setting that provides continuous electrocardiographic (ECG) monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Patients should continue to be monitored in this way for a minimum of three days. Additionally, patients should not be discharged within 12 hours of electrical or pharmacological conversion to normal sinus rhythm.
- **The dose of TIKOSYN must be individualized according to calculated creatinine clearance and QTc. (QT interval should be used if the heart rate is <60 beats per minute. There are no data on use of TIKOSYN when the heart rate is <50 beats per minute.)** The usual recommended dose of TIKOSYN is 500 mcg BID, as modified by the dosing algorithm described below. For consideration of a lower dose, see **Special Considerations** below.
- Serum potassium should be maintained within the normal range before TIKOSYN treatment is initiated and should be maintained within the normal range while the patient remains on TIKOSYN therapy. (See **WARNINGS, Hypokalemia and Potassium-Depleting Diuretics**). In clinical trials, potassium levels were generally maintained above 3.6–4.0 mEq/L.
- Patients with atrial fibrillation should be anticoagulated according to usual medical practice prior to electrical or pharmacological cardioversion. Anticoagulant therapy may be continued after cardioversion according to usual medical practice for the treatment of people with AF. Hypokalemia should be corrected before initiation of TIKOSYN therapy (see **WARNINGS, Ventricular Arrhythmia**).
- Patients to be discharged on TIKOSYN therapy from an inpatient setting as described above must have an adequate supply of TIKOSYN, at the patient's individualized dose, to allow uninterrupted dosing until the patient receives the first outpatient supply.
- TIKOSYN is distributed only to those hospitals and other appropriate institutions confirmed to have received applicable dosing and treatment initiation education programs. Inpatient and subsequent outpatient discharge and refill prescriptions are filled only upon confirmation that the prescribing physician has received applicable dosing and treatment initiation education programs. For this purpose, a list for use by pharmacists is maintained containing hospitals and physicians who have received one of the education programs.

### Instructions for Individualized Dose Initiation

#### Initiation of TIKOSYN Therapy

**Step 1.** Electrocardiographic assessment: Prior to administration of the first dose, the QTc must be determined using an average of 5–10 beats. If the QTc is greater than 440 msec (500 msec in patients with ventricular conduction abnormalities), TIKOSYN is contraindicated. If heart rate is less than 60 beats per minute, QT interval should be used. Patients with heart rates <50 beats per minute have not been studied.

**Step 2.** Calculation of creatinine clearance: Prior to the administration of the first dose, the patient's creatinine clearance must be calculated using the following formula:

$$\text{creatinine clearance (male)} = \frac{(140 - \text{age}) \times \text{actual body weight in kg}}{72 \times \text{serum creatinine (mg/dL)}}$$

$$\text{creatinine clearance (female)} = \frac{(140 - \text{age}) \times \text{actual body weight in kg} \times 0.85}{72 \times \text{serum creatinine (mg/dL)}}$$

When serum creatinine is given in  $\mu\text{mol/L}$ , divide the value by 88.4 ( $1 \text{ mg/dL} = 88.4 \mu\text{mol/L}$ ).

**Step 3.** Starting Dose: The starting dose of TIKOSYN is determined as follows:

<u>Calculated Creatinine Clearance</u>	<u>TIKOSYN Dose</u>
>60 mL/min	500 mcg twice daily
40 – 60 mL/min	250 mcg twice daily
20 – <40 mL/min	125 mcg twice daily
<20 mL/min	Dofetilide is contraindicated in these patients

**Step 4.** Administer the adjusted TIKOSYN dose and begin continuous ECG monitoring.

**Step 5.** At 2–3 hours after administering the first dose of TIKOSYN, determine the QTc. If the QTc has increased by greater than 15% compared to the baseline established in Step 1 OR if the QTc is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities), subsequent dosing should be adjusted as follows:


<u>If the Starting Dose Based on Creatinine Clearance is:</u>	<u>Then the Adjusted Dose (for QTc Prolongation) is:</u>
500 mcg twice daily	250 mcg twice daily
250 mcg twice daily	125 mcg twice daily
125 mcg twice daily	125 mcg once a day

**Step 6.** At 2–3 hours after each subsequent dose of TIKOSYN, determine the QTc (for in-hospital doses 2–5). No further down titration of TIKOSYN based on QTc is recommended.

NOTE: If at any time after the second dose of TIKOSYN is given the QTc is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities), TIKOSYN should be discontinued.

**Step 7.** Patients are to be continuously monitored by ECG for a minimum of three days, or for a minimum of 12 hours after electrical or pharmacological conversion to normal sinus rhythm, whichever is greater.

The steps described above are summarized in the following diagram:



## Maintenance of TIKOSYN Therapy

Renal function and QTc should be re-evaluated every three months or as medically warranted. If QTc exceeds 500 milliseconds (550 msec in patients with ventricular conduction abnormalities), TIKOSYN therapy should be discontinued and patients should be carefully monitored until QTc returns to baseline levels. If renal function deteriorates, adjust dose as described in **Initiation of TIKOSYN Therapy, Step 3**.

### Special Considerations

**Consideration of a Dose Lower than that Determined by the Algorithm:** The dosing algorithm shown above should be used to determine the individualized dose of TIKOSYN. In clinical trials (see **CLINICAL STUDIES**), the highest dose of 500 mcg BID of TIKOSYN as modified by the dosing algorithm led to greater effectiveness than lower doses of 125 or 250 mcg BID as modified by the dosing algorithm. The risk of Torsade de Pointes, however, is related to dose as well as to patient characteristics (see **WARNINGS**). Physicians, in consultation with their patients, may therefore in some cases choose doses lower than determined by the algorithm. It is critically important that if at any time this lower dose is increased, the patient needs to be rehospitalized for three days. Previous toleration of higher doses does not eliminate the need for rehospitalization.

The maximum recommended dose in patients with a calculated creatinine clearance greater than 60 mL/min is 500 mcg BID; doses greater than 500 mcg BID have been associated with an increased incidence of Torsade de Pointes.

A patient who misses a dose should NOT double the next dose. The next dose should be taken at the usual time.

**Cardioversion:** If patients do not convert to normal sinus rhythm within 24 hours of initiation of TIKOSYN therapy, electrical conversion should be considered. Patients continuing on TIKOSYN after successful electrical cardioversion should continue to be monitored by electrocardiography for 12 hours post cardioversion, or a minimum of 3 days after initiation of TIKOSYN therapy, whichever is greater.

### Switch to TIKOSYN from Class I or other Class III Antiarrhythmic Therapy

Before initiating TIKOSYN therapy, previous antiarrhythmic therapy should be withdrawn under careful monitoring for a minimum of three (3) plasma half-lives. Because of the unpredictable pharmacokinetics of amiodarone, TIKOSYN should not be initiated following amiodarone therapy until amiodarone plasma levels are below 0.3 mcg/mL or until amiodarone has been withdrawn for at least three months.

### Stopping TIKOSYN Prior to Administration of Potentially Interacting Drugs

If TIKOSYN needs to be discontinued to allow dosing of other potentially interacting drug(s), a washout period of at least two days should be followed before starting the other drug(s).

## HOW SUPPLIED

TIKOSYN<sup>®</sup> 125 mcg (0.125 mg) capsules are supplied as No. 4 capsules with a light orange cap and white body, printed with TKN 125 PFIZER, and are available in:

TIKOSYN<sup>®</sup> 250 mcg (0.25 mg) capsules are supplied as No. 4 capsules, peach cap and body, printed with TKN 250 PFIZER, and are available in:

TIKOSYN<sup>®</sup> 500 mcg (0.5 mg) capsules are supplied as No. 2 capsules, peach cap and white body, printed with TKN 500 PFIZER, and are available in:

	125 mcg (0.125 mg)	250 mcg (0.25 mg)	500 mcg (0.5 mg)
Obverse	TKN 125	TKN 250	TKN 500
Reverse	PFIZER	PFIZER	PFIZER
Bottle of 14	0069-5800-61	0069-5810-61	0069-5820-61
Bottle of 60	0069-5800-60	0069-5810-60	0069-5820-60
Unit dose / 40	0069-5800-43	0069-5810-43	0069-5820-43

Store at controlled room temperature, 15° to 30°C (59° to 86°F).

PROTECT FROM MOISTURE AND HUMIDITY.

Dispense in tight containers (USP).

**Rx only**



LAB-0067-6.1

Revised Month 2013

**MEDICATION GUIDE**  
**TIKOSYN® (Tee' ko sin)**  
**(dofetilide) Capsules**

Read the Medication Guide before you start taking TIKOSYN and each time you get a refill. This information does not take the place of talking with your doctor about your condition or treatment.

**What is the most important information I should know about TIKOSYN?**

TIKOSYN can cause serious side effects, including a type of abnormal heartbeat called Torsade de Pointes, which can lead to death.

To establish the right dose of TIKOSYN, treatment with TIKOSYN must be started in a hospital where your heart rate and kidney function will be checked for the first 3 days of treatment. It is important that when you go home, you take the exact dose of TIKOSYN that your doctor prescribed for you.

While you take TIKOSYN, always watch for signs of abnormal heartbeat.

Call your doctor and go to the hospital right away if you:

- feel faint
- become dizzy, or
- have a fast heartbeat

**What is TIKOSYN?**

TIKOSYN is a prescription medicine that is used to treat an irregular heartbeat (atrial fibrillation or atrial flutter).

It is not known if TIKOSYN is safe and effective in children under 18 years of age.

**Who should not take TIKOSYN?**

Do not take TIKOSYN if you:

- have an irregular heartbeat called long QT syndrome
- have kidney problems or are on kidney dialysis
- take any of these medicines:
  - cimetidine (TAGAMET, TAGAMET HB)\*
  - verapamil (CALAN, CALAN SR, COVERA-HS, ISOPTIN, ISOPTIN SR, VERELAN, VERELAN PM, TARKA)\*
  - ketoconazole (NIZORAL, XOLEGEL, EXTINA)\*
  - trimethoprim alone (PROLOPRIM, TRIMPEX)\* or the combination of trimethoprim and sulfamethoxazole (BACTRIM, SEPTRA SULFATRIM)\*
  - prochlorperazine (COMPAZINE, COMPO)\*
  - megestrol (MEGACE)\*
  - dolutegravir (TIVICAY)
  - hydrochlorothiazide alone or in combination with other medicines (such as ESIDRIX, EZIDE, HYDRODIURIL, HYDRO-PAR, MICROZIDE, or ORETIC)\*

Ask your doctor if you are not sure if any of your medicines are the kind listed above.

- are allergic to dofetilide in TIKOSYN. See the end of this leaflet for a complete

list of ingredients in TIKOSYN.

### **What should I tell my doctor before taking TIKOSYN?**

Before taking TIKOSYN, tell your doctor about all of your medical conditions including if you:

- have heart problems
- have kidney or liver problems
- are pregnant or plan to become pregnant. It is not known if TIKOSYN will harm your unborn baby.
- are breast-feeding or plan to breast-feed. It is not known if TIKOSYN passes into your breast milk. You and your doctor should decide if you will take TIKOSYN or breast-feed. You should not do both.

Especially tell your doctor if you take medicines to treat:

- heart problems
- high blood pressure
- depression or other mental problems
- asthma
- allergies, or hay fever
- skin problems
- infections

Ask your doctor if you are not sure about the medicines you take. Tell your doctor about all prescription and non-prescription medicines, vitamins, dietary supplements, and any natural or herbal remedies. TIKOSYN and other medicines may affect each other, causing serious side effects. If you take TIKOSYN with certain medicines, you will be more likely to have a different type of abnormal heartbeat. See “Who should not take TIKOSYN?”

Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.

### **How should I take TIKOSYN?**

- Take TIKOSYN exactly as your doctor tells you.
- Do not change your TIKOSYN dose unless your doctor tells you to.
- Your doctor will do tests before you start and while you take TIKOSYN.
- Do not stop taking TIKOSYN until your doctor tells you to stop. If you miss a dose, just take the next dose at your regular time. **Do not take 2 doses of TIKOSYN at the same time.**
- TIKOSYN can be taken with or without food.
- If you take too much TIKOSYN, call your doctor or go to the nearest hospital emergency room right away. Take your TIKOSYN capsules with you to show to the doctor.

### **What are the possible side effects of TIKOSYN?**

TIKOSYN can cause serious side effects, including a type of abnormal heartbeat called Torsade de Pointes, which can lead to death. See “What is the most important information I should know about TIKOSYN?”

The most common side effects of TIKOSYN include:

- headache

- chest pain
- dizziness

Call your doctor right away if you have signs of electrolyte imbalance:

- severe diarrhea
- unusual sweating
- vomiting
- not hungry (loss of appetite)
- increased thirst (drinking more than normal)

Tell your doctor if you have any side effects that bother you or do not go away.

These are not all the possible side effects of TIKOSYN. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### **How should I store TIKOSYN?**

- Store TIKOSYN between 59° to 86°F (15° to 30°C).
- Keep TIKOSYN away from moisture and humidity.
- Keep TIKOSYN in a tightly closed container.
- Keep TIKOSYN and all medicines out of the reach of children.

### **General information about TIKOSYN**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TIKOSYN for a condition for which it was not prescribed. Do not give TIKOSYN to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about TIKOSYN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about TIKOSYN that is written for health professionals.

For more about TIKOSYN, go to [www.tikosyn.com](http://www.tikosyn.com) or call **1-877-TIKOSYN (1-877-845-6796)**.

### **What are the ingredients in TIKOSYN?**

**Active ingredient:** dofetilide

**Inactive ingredients:**

**Capsule fill:** microcrystalline cellulose, corn starch, colloidal silicon dioxide, and magnesium stearate

**Capsule shell:** gelatin, titanium dioxide, and FD&C Yellow 6

**Imprinting ink:** iron oxide black, shellac, n-butyl alcohol, isopropyl alcohol, propylene glycol, and ammonium hydroxide

\* Listed trademarks are the property of their respective owners.

**Rx only**



*Distributed by*

**Pfizer Labs**

Division of Pfizer Inc, NY, NY 10017

LAB-0405-1.1

Revised Month 2013

This Medication Guide has been approved by the U.S. Food and Drug Administration.

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**020931Orig1s001**

**CLINICAL PHARMACOLOGY AND  
BIOPHARMACEUTICS REVIEW(S)**

## CLINICAL PHARMACOLOGY & BIOPHARMACEUTICS REVIEW

---

<b>NDA:</b>	<b>20,931</b>	<b>SLR-001</b>
<b>Submission Dates:</b>	March 19, March 24, and July 30, 2004	
<b>Drug Name:</b>	Tikosyn (dofetilide) capsules	
<b>Applicant:</b>	Pfizer Ireland Pharmaceuticals	
<b>Submission:</b>	Supplemental NDA, labeling changes	
<b>Reviewer:</b>	Elena V. Mishina, Ph.D.	

---

### 1 EXECUTIVE SUMMARY

This NDA review evaluates whether the sponsor has adequately addressed the labeling changes for Tikosyn (dofetilide) capsules derived from the results of the study characterizing the effects of hydrochlorothiazide (HCTZ) and triamterene on the pharmacokinetics and pharmacodynamics of dofetilide.

### 2 RECOMMENDATIONS:

The Office of Clinical Pharmacology and Biopharmaceutics, Division of Pharmaceutical Evaluation I has reviewed the information included in the Supplement **SLR-001** to NDA **20,931**. The Office of Clinical Pharmacology and Biopharmaceutics recommends adopting the proposed language for the labeling.

\_\_\_\_\_  
Elena Mishina, Ph. D.  
Clinical Pharmacology Reviewer

Date \_\_\_\_\_

\_\_\_\_\_  
Patrick Marroum, Ph. D.  
Cardio-Renal Team Leader

cc list: NDA 20,931, MehulM, MarroumP, MishinaE, HFD 110 BIOPHARM

### 3 TABLE OF CONTENTS

1	EXECUTIVE SUMMARY.....	1
2	RECOMMENDATIONS: .....	1
3	TABLE OF CONTENTS .....	2
4	SUMMARY OF CPB FINDINGS .....	2
4.1	BACKGROUND:.....	2
4.2	CURRENT SUBMISSION:.....	3
5	REVIEWER COMMENTS .....	3
6	QUESTION BASED REVIEW.....	6
7	APPENDIX.....	13
7.1	PROPOSED PACKAGE INSERT.....	14
7.2	INDIVIDUAL STUDY SUMMARY .....	41
7.1.2	STUDY PROTOCOL A115-1007.....	41

### 4 SUMMARY OF CPB FINDINGS

#### 4.1 Background:

Pfizer Inc. is seeking to update the professional and patient labeling with potential drug-drug interaction information regarding HCTZ and triameterene.

TIKOSYN is a Vaughan Williams Class III antiarrhythmic drug. TIKOSYN (dofetilide) increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. The increase in QT interval observed on the surface ECG is a result of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles. TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes. TIKOSYN should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). TIKOSYN is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min). The usual recommended dose of TIKOSYN is 500 mcg BID.

## 4.2 Current Submission:

The primary objective of this Application was to update the Package Insert with the information on drug-drug interaction. The sponsor proposed to add hydrochlorothiazide diuretics to the CONTRAINDICATIONS Section and upgrade of the cautionary language regarding serum potassium.

In this Application, NDA 20,931 SLR-001, the sponsor included the results of one study A115-1007 “An Open, Randomized, Placebo Controlled Parallel Group Study In Healthy Volunteers To Investigate The Effects Of Hydrochlorothiazide (HCTZ) And Triamterene On The Steady State Pharmacokinetics And Pharmacodynamics Of Dofetilide.”

## 5 REVIEWER COMMENTS

### *GENERAL*

1. The Agency considered that the information provided in the Supplement No. SLR 001 to NDA 20-931, for Tikosyn capsules appropriate to make the proposed labeling changes.

### *CLINICAL PHARMACOLOGY COMMENTS*

2. For both combination treatments, dofetilide and HCTZ, and dofetilide, triamterene, and HCTZ, AUC<sub>t</sub> and CL/f values were statistically different from the treatment with dofetilide and placebo ( $p < 0.01$ ). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and C<sub>max</sub> by 21%. In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and C<sub>max</sub> by 16%. Additionally, T<sub>max</sub> and CL<sub>r</sub> for dofetilide and HCTZ treatment vs dofetilide and placebo treatment and CL<sub>r</sub> for dofetilide, triamterene, and HCTZ treatment vs dofetilide and placebo treatment differ significantly ( $p < 0.05$ ).
3. As it was shown previously, females had lower dofetilide plasma concentrations (smaller AUC and C<sub>max</sub>) and faster clearance than in males. Creatinine clearance and body weight were the statistically significant covariates ( $p < 0.01$ ) comparing gender for AUC<sub>t</sub>, CL/f, and CL<sub>NR</sub>/f. However, test for treatment by gender interaction did not show any significant gender influence in this study.
4. In Tables 5.1.1 – 5.1.3 the sponsor displayed the pharmacokinetic parameters calculated for the individual patients, and the values of their mean, standard deviation coefficient of variation, difference between day 11 and day 4, and ratio between day 11 and day 4 for each treatment group. The descriptive statistics of these parameters are summarized in Table 5.2.1. None of the descriptive statistics values for AUC, C<sub>max</sub>, T<sub>max</sub>, and CL/f shown in Tables 5.1.1 – 5.1.3 are the same as in Table 5.2.1 (the values from the later Table are included in the study report). The sponsor did not attempt to explain the discrepancy in the results in these two tables.

5. In this study, dofetilide administration for 11 days QTc prolongation was 2 fold higher in comparison with the previously available data (PI). The sponsor did not explain this discrepancy. Between gender comparison on Day 4 of receiving dofetilide revealed a marginal differences ( $p=0.0541$ ) between two groups.

**Labeling Comments: (an annotated labeling is provided)**

1. CONTRAINDICATIONS

“The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with TIKOSYN is contraindicated (see PRECAUTIONS, Drug-Drug Interactions) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation.”

2. PRECAUTIONS

Hypokalemia and Potassium-Depleting Diuretics

Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics, increasing the potential for torsade de pointes. Potassium levels should be within the normal range prior to administration of TIKOSYN and maintained in the normal range during administration of TIKOSYN. (see DOSAGE AND ADMINISTRATION).

Drug Interactions

Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: (see CONTRAINDICATIONS) Concomitant use of HCTZ alone or in combination with triamterene is contraindicated. HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%. However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase). In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and Cmax by 16%. However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase). The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium. In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).

3. DOSAGE AND ADMINISTRATION

- Serum potassium should be maintained within the normal range before TIKOSYN treatment is initiated and should be maintained within the normal range while the patient

remains on TIKOSYN therapy. (See WARNINGS, Hypokalemia and Potassium Depleting Diuretics) In clinical trials potassium levels were generally maintained above 3.6-4.0 mEq/L.

APPEARS THIS WAY ON  
ORIGINAL



## 6 QUESTION BASED REVIEW

*What was the rationale for this study?*

Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide. The population pharmacokinetic analysis of the Phase III data indicated that the concomitant use of thiazide diuretics was associated with a 16% reduction in the clearance of dofetilide. The present study was designed to assess the effects of the thiazide diuretic HCTZ on the pharmacokinetics and pharmacodynamics of dofetilide. In addition, the study assessed the effects of the combination of HCTZ plus triamterene, which is commonly co-administered with HCTZ. Triamterene is a potassium sparing diuretic and was selected for this study since it is also a substrate for the renal cation transport system. It therefore has the potential to compete with dofetilide for renal secretion.

Since the exposure and pharmacodynamic effects (QTc prolongation) of dofetilide are directly correlated, the results of this study would allow assessing if concomitant administrations of these diuretics with dofetilide should be contraindicated.

*Was the pharmacokinetics of dofetilide affected by coadministration of HCTZ and HCTZ + triamterene?*

Yes. When HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose), the exposure to dofetilide (measured by AUC<sub>t</sub> and C<sub>max</sub> at steady state) was significantly larger ( $p < 0.01$ ) in both groups with combination treatments with diuretics when compared to dofetilide alone. In patients receiving HCTZ alone, dofetilide AUC increased by 27% and C<sub>max</sub> by 21%. In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and C<sub>max</sub> by 16%. The dofetilide clearance values decreased from Day 4 to 11 in all groups and differences were statistically significant ( $p < 0.01$ ). The differences in T<sub>max</sub> and renal clearance for dofetilide from Day 4 to Day 11 were statistically significant ( $p < 0.05$ ). Changes in renal clearance between Day 4 and 11 for all groups were not statistically significant (Table 4, study summary). The mean dofetilide plasma concentrations vs time on Day 11 are compared in Figure 1.




Figure 1. Mean plasma dofetilide concentrations vs after dofetilide and placebo (dashed line), dofetilide and HCTZ (solid line) and dofetilide and HCTZ and triamterene (dotted line) on Day 11.

In patients receiving HCTZ alone, dofetilide AUC increased by 26% and C<sub>max</sub> by 21%. In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and C<sub>max</sub> by 16% (Table 1).

Table 1. Comparison of the pharmacokinetic parameters for three treatments.

	Mean		Means Ratio <sup>(a)</sup> or Difference <sup>(b)</sup>
	Day 4	Day 11	
Dofetilide + HCTZ			
AUC <sub>t</sub> (ng.h/ml)	16.6	21.0	1.26 <sup>(a)</sup>
C <sub>max</sub> (ng/ml)	2.43	2.95	1.21 <sup>(a)</sup>
Dofetilide + HCTZ+ triamterene			
AUC <sub>t</sub> (ng.h/ml)	18.2	23.7	1.30 <sup>(a)</sup>
C <sub>max</sub> (ng/ml)	2.83	3.29	1.16 <sup>(a)</sup>
Dofetilide + Placebo			
AUC <sub>t</sub> (ng.h/ml)	15.8	17.4	1.10 <sup>(a)</sup>
C <sub>max</sub> (ng/ml)	2.25	2.66	1.18 <sup>(a)</sup>

*Were the pharmacokinetics in males in females different?*

No. The sponsor compared the pharmacokinetic parameters on Day 4 (only dofetilide) by gender and found that gender effect on AUC, CL/f and CL<sub>NR</sub>/f was not significant in this study (ANOVA).

However, creatinine clearance and weight were statistically significant when added as covariates to the analysis of the following pharmacokinetic parameters: AUC, CL/f and CL<sub>NR</sub>/f (Table 2).

Table 2. Comparison of Pharmacokinetic Parameters by Gender (Day 4).

Parameter	Covariate	Ratio Males/Females	90% CI of Covariate	Significance, p-value	Between Gender Comparison, p-value
AUC <sub>t</sub>	none	1.02	(0.93, 1.13)	-	0.7026
	CL <sub>cr</sub>	1.15	(1.04, 1.26)	0.0001	0.0188
	BWT	1.23	(1.06, 1.42)	0.0105	0.0237
C <sub>max</sub>	none	1.04	(0.93, 1.16)	-	0.5754
	CL <sub>cr</sub>	1.15	(1.02, 1.29)	0.0059	0.0622
	BWT	1.19	(0.99, 1.42)	0.1144	0.1130
<b>Difference Between Males and Females</b>					
CL/f	none	-9.38	(- 60.38, 41.63)	-	0.3373
	CL <sub>cr</sub>	-69.20	(-118.77, -19.63)	0.2777	0.0235
	BWT	-104.71	(-181.55, -27.87)	0.0106	0.0268
CL <sub>NR</sub> /f	none	-32.16	(-91.24, 26.93)	-	0.3648
	CL <sub>cr</sub>	-70.99	(-136.93, -5.05)	0.0001	0.0774
	BWT	-158.14	(-244.69, -71.59)	0.0034	0.0038

In the existing Package Insert, the results of a population pharmacokinetic analysis showed that women have approximately 12-18% lower dofetilide oral clearances than men (14-22% greater plasma dofetilide levels), after correction for weight and creatinine clearance.

*How was the pharmacodynamics of dofetilide affected by coadministration of HCTZ and HCTZ + triamterene?*

Despite the slight changes in pharmacokinetic, the changes in pharmacodynamic of dofetilide were much more intense after coadministration with diuretics.

Figure 2 compares the changes in QTc over time after three treatments.




Figure 2. Comparison of QTc changes after three treatments.

In patients receiving HCTZ and dofetilide, QTc increased over time (measured as AUECt) by 197% and maximum QTc increased by 95%. In patients receiving HCTZ, triamterene and dofetilide, QTc increased over time (measured as AUECt) by 190% and the maximum QTc increased by 84%. The changes between day 4 and day 11 in patients receiving dofetilide alone were not statistically significant. Table 3 below compares the PD parameters obtained on Day 4 and Day 11 after three treatments.

Table 3. Comparison of PD parameters after three treatments Day 4 vs Day 11

Parameter	Treatment	Mean Day 4	Mean Day 11	Ratio	Comparison with placebo (p)
<b>Dofetilide + Placebo</b>					
AUECt, msec.hr		148.6(134.8)	174.2(164.1)	1.17	
QTc, msec		43.9(17.3)	43.9(24.8)	1.00	
<b>Dofetilide + HCTZ</b>					
AUECt, msec.hr		189.2(194.4)	561.2(258.5)	2.97	<0.001
QTc, msec		50.3(20.3)	97.9(41.9)	1.95	<0.001
<b>Dofetilide + HCTZ + triamterene</b>					
AUECt, msec.hr		179.4(133.7)	520.5(249.1)	2.90	<0.001
QTc, msec		45.4(14.8)	83.4(44.5)	1.84	0.0028

*Were the pharmacodynamics in males and females different?*

Yes. The sponsor compared the mean change in QTc interval vs time for female and male subjects on Day 4 (Figure 3). Female subjects had a larger (mean value 49.8 msec) increase of the QTc interval than males (mean value 34.5 msec). Due to high interpatient variability, the difference between genders was marginal (p=0.0541, 95% CI -19.51, 0.18).




Figure 3. Mean changes in 3-lead QTc after three treatments on Day 4, male and female subjects.

Since in the original NDA the relationship between the effect and dofetilide plasma concentration was described with a linear model, the sponsor fitted a regression lines to the effect vs dofetilide plasma concentration data and compared the slopes for three treatments as well as gender effect. The slopes for each of the combination treatments were not statistically different from the treatment with dofetilide alone. The difference between slopes estimated on day 4 for gender were not statistically significant ( $p=0.063$ ). The trellis graphs compare the areas under the QTc changes vs time (Figure 4) and QTc changes vs time (Figure 5) for the three treatments and for gender differences.




Figure 4. Trellis plot of the mean AUECt comparison for gender (0-males, 1-females) and treatments (1-dofetilide, 2-dofetilide+HCTZ, 3-dofetilide+HCTZ+ triamterene).

Both combination treatments prolonged QTc in females on average more than 100 msec. In males, dofetilide with HCTZ led to a larger QTc prolongation (mean 90 msec) than dofetilide with HCTZ and triamterene (mean 62 msec).




Figure 2. Trellis plot of the mean changes in QTc for each treatment (1-dofetilide, 2-dofetilide + HCTZ, 3- dofetilide + HCTZ + triamterene), males, sex=0; females, sex=1.

The sponsor explained the pharmacodynamic effects by a combination of the increase in dofetilide exposure and the reductions in serum potassium. The influence of serum potassium was assessed statistically using ANOVA. The sponsor analyzed the influence of the following covariates: serum sodium, potassium, calcium and magnesium on the PD parameters. Only serum potassium had a significant effect on both Emax (P=0.0136) and AUECt (p=0.0146). The mean serum potassium values over time are shown in Figure 6, in the Appendix.

The differences between treatments in AUECt, and Emax were reduced when adjusted for the observed changes in serum potassium. The mean differences in AUEC between the dofetilide + HCTZ and dofetilide + placebo groups (212.4msec.h, 95% CI (36.5, 398.4) and between the dofetilide + HCTZ + triamterene and dofetilide + placebo groups (252.3msec.h, 95% CI: 115.1, 389.5) remained statistically significant. These differences were not statistically significant for Emax.

The sponsor presented the following table to show the changes observed in serum potassium levels between Day 4 and Day 11. However, Table 5.8 in the study report does not have the serum potassium data on day 4. For the dofetilide and HCTZ treatment, serum potassium was measured at baseline and then on Day 5 and daily after that. For the dofetilide and HCTZ and triamterene treatment, serum potassium was measured at baseline and then on Day 3, day 5 and daily after that. The AUEC and Emax values presented are the predicted differences (Day 11 - Day 4) based on the observed changes in serum potassium. However, the model that could predict changes in AUECt and QTC was not described in the report.

**Changes observed in serum potassium levels and influence on pharmacodynamic results**

Parameter	Arithmetic Means	
	Dofetilide + HCTZ	Dofetilide + HCTZ + Triamterene
	Day 11 - Day 4 <sup>d</sup>	Day 11 - Day 4 <sup>d</sup>
Serum potassium (meq/l)	-0.8	-0.4
AUEC <sub>τ</sub> (msec.h) <sup>e</sup>	181.0	89.0
E <sub>max</sub> (msec) <sup>e</sup>	34.8	17.1

The serum potassium was lower in the two diuretic groups compared with the control and additional exploratory analyses were performed to assess the impact of this on QTc. These analyses indicated a consistent statistically significant effect of serum potassium for both E<sub>max</sub> (p=0.0136) and AUEC<sub>τ</sub> (p=0.0146), which increased as serum potassium levels decreased. Using a linear model to relate the effect of serum potassium and dofetilide plasma concentrations on QTc allowed quantification of the effect. In the dofetilide + HCTZ group, 34.8msec of the 47.6msec (73%) observed increase in QTc could be explained by a drop in serum potassium of 0.8meq/L and 10.76msec could be explained by the increase in C<sub>max</sub>. In the dofetilide + HCTZ + triamterene group, 17.1 msec of the 38.1 msec (45%) observed increase in QTc could be explained by a drop in serum potassium of 0.4meq/l and 7.37msec could be explained by the increase in C<sub>max</sub>.

## 7 APPENDIX

APPEARS THIS WAY ON ORIGINAL



## 7.1 Proposed Package Insert

**TIKOSYN**®  
(dofetilide)  
Capsules

(b) (4)



## 7.2 Individual Study Summary

### 7.1.2 STUDY PROTOCOL A115-1007

**TITLE:** “An Open, Randomized, Placebo Controlled Parallel Group Study In Healthy Volunteers To Investigate The Effects Of Hydrochlorothiazide (HCTZ) And Triamterene On The Steady State Pharmacokinetics And Pharmacodynamics Of Dofetilide.”

**Principal Investigator:** Dr. T. Duvauchelle

**Study Dates:** 5 July 1999 -13 September 1999

**Phase of Development:** Phase I

#### **Objectives:**

To investigate the effects of multiple doses HCTZ and the combination of HCTZ plus triamterene on the steady state pharmacokinetics of dofetilide in healthy volunteers.

To evaluate the effect of any alteration of the pharmacokinetic profile of dofetilide on its pharmacodynamics as assessed from QTc intervals.

To investigate the safety and toleration of the coadministration of HCTZ and dofetilide and HCTZ plus triamterene and dofetilide.

**Study Design:** This was an open, randomized, placebo controlled parallel group study in healthy subjects, to investigate the effects of hydrochlorothiazide (HCTZ) and triamterene on the steady state pharmacokinetics and pharmacodynamics of dofetilide.

#### **Diagnoses and Criteria for Inclusion of Subjects:**

Healthy male and female subjects aged 18 to 45 years inclusive and weight between 60 (50kg for female subjects) and 100kg.

#### **Drug Administration:**

##### *Dosage Form*

Dofetilide	2 x 250 mg commercial capsules (FID S00114AD, Lot nos. 4721-139 and 5134-063)
HCTZ	50 mg tablets (hydrosaluric, Lot no. HH10320)
HCTZ plus triamterene	tablet containing 50 mg triamterene plus 25 mg HCTZ (dyazide, Lot no.004071)
Placebo	tablets (FID SO0425AB. Lot no.5134-052)
Potassium chloride	Sando-K effervescent tablets (Lot no. 063A9).

##### *Dosing*

All subjects were treated with dofetilide (500 mg bid x 10 days, single dose only on the morning of Day 11). On study Days 5 and 6, eight male and eight female subjects received concomitant treatment with HCTZ (50 mg QD) and eight male and eight female subjects received concomitant treatment with HCTZ plus triamterene (25/50 mg QD).

The remaining eight subjects received placebo. On study Day 7 the dose of HCTZ was increased to 100 mg. Similarly, the dose of HCTZ plus triamterene was increased to 50/100 mg. Both doses were administered at the same time as the morning dose of dofetilide. Concomitant drug administration lasted seven days including the morning dose on Day 11. All drugs were taken under supervision in the unit and were taken by the subject while sitting or standing with approximately 250 mL water. There was a mouth check to ensure compliance. The morning dose of the drug was administered between approximately 08:00 and 10:00 hours and the evening dose was given 12 hours later.

#### **Pharmacokinetic, Pharmacodynamic and Safety Evaluations:**

For pharmacokinetics, on study Days 1 to 3 and 5 to 10, trough blood samples (5mL) were taken pre-morning dose only. On study Days 4 and 11, blood samples (5mL) were taken at time 0 (prior to the morning dose) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 hours post dose. On study Day 1, a 10 mL pre-dose urine sample was collected. On study Days 4 and 11, subjects emptied their bladders prior to dosing and a 12 hour collection was made. The volume of urine collected was recorded and a 10 mL aliquot was taken and frozen until assay.

For pharmacodynamics, on study Day 1, 3-lead an ECG measurements (leads II, aVF and V5) were made pre-dose (six replicate measurements). On study Days 4 and 11, 3-lead ECG measurements were made approximately at the same times as the blood samples. The blood sample was taken first and then an ECG measurement was taken. ECGs were recorded pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 hours post dose after the subject had been lying flat in a quiet environment for five minutes. Hard copy 3-lead ECGs with lead II rhythm strip were digitized using a previously validated digitizing pad and computer program. At each time point the ECG traces were evaluated for suitability for data capture on the basis of the quality of the ECG tracing. Each acceptable beat was measured and an average ECG interval generated. The same lead (preferably lead II) was used throughout each individual. Accurate determinations of PR, QRS, QT and RR intervals and evaluation of QTc prolongation were made using the same lead throughout.

#### **Analytical Methods:**

All plasma and urine dofetilide concentration measurements were carried out at (b) (4).  
(b) (4) A validated radioimmunoassay was used to determine dofetilide concentration in plasma and urine samples.

The analytical procedure employed was a competitive RIA in which 3H-labelled dofetilide (UK-68,798) competes with dofetilide (UK-68,798) for a limited number of binding sites on sheep dofetilide antiserum. After incubation, separation of bound drug from free drug was achieved by adding a second antibody plus polyethylene glycol 8000. The antibody free fraction was measured using a liquid scintillation counter, the concentration of dofetilide in the sample being directly proportional to the measured radioactivity.

During the study the overall imprecision value (CV) for plasma analysis was 16.8, 8.7 and 10.4% at nominal dofetilide concentrations of 281, 803 and 1506 pcg/ml respectively. The inaccuracy (bias) of the assay at all concentrations ranged from -6.8 to 8.2%. The CV for urine analysis was 10.6, 6.0, and 8.4% at target dofetilide

concentrations of 281, 803 and 1506 pg/ml respectively. The inaccuracy (bias) of the assay at all concentrations ranged from -12.6 to 9.2%. The lower limit of quantification was 0.1ng/ml and the upper limit of the calibration curve was nominally 2.00 ng/ml for both plasma and urine.

### Parameter Calculation

#### Pharmacokinetics:

AUC <sub>t,ss</sub>	Area under the plasma concentration time curve over the dosing interval (from 0-12 hours) at steady state (calculated using the linear trapezoidal method)
C <sub>max,ss</sub>	Maximum observed plasma concentration at steady state (obtained from recorded data)
T <sub>max</sub>	The first time to occurrence of C <sub>max</sub> (obtained from recorded data).
CL/f	Total oral clearance (calculated as dose/AUC <sub>t</sub> ).

#### For the urine samples data analyses:

A <sub>et</sub>	Amount of unchanged drug excreted in urine
CL <sub>R</sub>	renal clearance (calculated as A <sub>et</sub> (0-12h)/AUC <sub>t</sub> ).
CL <sub>NR</sub> /f	non-renal clearance (calculated as CL/f -CL <sub>R</sub> ).

#### Pharmacodynamics:

E <sub>max</sub>	The maximum observed QTc (Bazett's) or increase from baseline in QTc was obtained directly from the experimental data
AUEC <sub>t</sub>	The area under the (QTc or increase in QTc) effect-time curve from time 0 to a specified time t was calculated using the linear trapezoidal method
Slope	The slope of the QTc or change in QTc versus dofetilide plasma concentration plot was estimated by linear regression. No effect compartment modeling was used.

Maximum change in QTc and its first time of occurrence were obtained directly from the recorded data for days 4 and 11 using the mean of the 6 predose values on day 1 as a baseline.

### Statistical Methods:

Statistical analysis was performed on the following pharmacokinetic parameters: log transformed AUC<sub>t</sub> and C<sub>max</sub>, T<sub>max</sub>, CL/f, A<sub>et</sub>, CL<sub>R</sub> and CL<sub>NR</sub>/f. The difference between Days 11 and 4 (Day 11- Day 4) for each pharmacokinetic parameter was subject to an analysis of variance (ANOVA). The ANOVA contained the terms: treatment, gender and treatment by gender interaction. The interaction term was dropped when not found to be significant at the 10% level. The following comparisons were considered: Dofetilide + HCTZ versus dofetilide alone; dofetilide + HCTZ + triamterene versus dofetilide alone. The differences between adjusted means or ratios of adjusted geometric means (as appropriate) and their corresponding 90% confidence intervals were presented. Additionally, differences between males and females on Day 4 were examined for the same pharmacokinetic parameters and the differences between adjusted means or ratios of adjusted geometric means (as appropriate) and their corresponding 90% confidence

intervals were presented. An analysis of covariance (also looking at differences between genders) was carried out adjusting for creatinine clearance (CLcr) as one analysis and adjusting for weight as another.

The pharmacodynamic parameters analyzed statistically were: area under effect curve (AUECt) change from baseline QTc and Emax change from baseline QTc. The baseline was defined as the mean of all measurements up to Day 5 pre-dose. The difference between Day 11 and Day 4 was subject to the analysis of variance in exactly the same way as for the pharmacokinetic data except that 95% confidence intervals were used. Gender differences on Day 4 were examined in the same way as for the pharmacokinetic data except that 95% confidence intervals were used. An analysis of covariance for the pharmacodynamic parameters was carried out adjusting for changes in serum electrolytes (sodium, potassium, magnesium and calcium).

**Results:**

*Subject Disposition*

Fifty-one subjects (Table 1) were randomized to one of three parallel groups. Of these 51 subjects, 48 subjects completed the study, 16 in each parallel group (dofetilide + HCTZ, dofetilide + HCTZ + triamterene or dofetilide + placebo). Three of subjects discontinued from the study during the dofetilide only phase, two due to abnormal ECG readings and one withdrew consent (Table 1).

Table 1. Subjects Disposition

<b>Evaluation Groups:</b>	<b>Dofetilide only</b>	<b>Dofetilide + HCTZ</b>	<b>Dofetilide + HCTZ + Triamterene</b>	<b>Dofetilide + placebo</b>
	<b>Days 1-4</b>	<b>Days 5-11</b>	<b>Days 5-11</b>	<b>Days 5-11</b>
<b>Entered Study</b>	<b>51</b>	<b>16</b>	<b>16</b>	<b>16</b>
<b>Completed Study</b>	<b>48</b>	<b>16</b>	<b>16</b>	<b>16</b>
<b>Discontinued</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Evaluated for Pharmacokinetics and Pharmacodynamics</b>	<b>48</b>	<b>16</b>	<b>16</b>	<b>16</b>
<b>Assessed for safety:</b>				
<b>Adverse events</b>	<b>51</b>	<b>16</b>	<b>16</b>	<b>16</b>
<b>Laboratory tests</b>	<b>51</b>	<b>16</b>	<b>16</b>	<b>16</b>

*Baseline Characteristics*

There were 24 males and 27 females recruited into the study. In the dofetilide + HCTZ group, the mean ages for males and females were 24 and 26 years, respectively. In the dofetilide + HCTZ + triamterene group, the mean ages for males and females were 29 and 26 years, respectively. The mean ages of males and females in the dofetilide + placebo group were 24 and 25 years, respectively. Males were an average height of 181cm in the dofetilide + HCTZ group, 176cm in the dofetilide + HCTZ + triamterene group and 180 cm in the dofetilide + placebo group. Females were an average height of 164 cm in the dofetilide + HCTZ group and 166 cm in both the dofetilide + HCTZ + triamterene group and the dofetilide + placebo group. For the dofetilide + HCTZ group

and the dofetilide + HCTZ + triamterene group, the mean weights for males and females were 74 kg and 59 kg, respectively. The mean weights of males and females in the dofetilide + placebo group were 77 kg and 58 kg, respectively

**Pharmacokinetics**

The comparison of the dofetilide pharmacokinetic parameters by group is shown in Table 2 below.

Table 2. PK Parameters.

Parameter	Raw Means (n =16)					
	Dofetilide + HCTZ		Dofetilide + HCTZ + Triamterene		Dofetilide + Placebo	
	Day 4	Day 11	Day 4	Day 11	Day 4	Day 11
AUC <sub>t</sub> (ng.h/ml)	16.6	21.0	18.2	23.7	15.8	17.4
C <sub>max</sub> (ng/ml)	2.43	2.95	2.83	3.29	2.25	2.66
T <sub>max</sub> (h)	1.78	2.63	1.94	1.94	2.20	1.80
CL/f (ml/min)	511.0	403.9	462.3	356.9	540.4	488.4
Ae <sub>t</sub> (mcg)	353.9	319.4	357.2	370.2	321.2	363.4
CL <sub>r</sub> (ml/min)	372.2	277.3	341.1	272.7	360.6	377.8
CL <sub>NR</sub> /f (ml/min)	158.5	148.4	138.3	96.9	205.6	135.7

Means are geometric for AUC<sub>t</sub> and C<sub>max</sub>, arithmetic for T<sub>max</sub> CL/f, Ae<sub>t</sub> CLR and CLNR/f. For Ae<sub>t</sub>, CLR and CLNR/f means are based on subjects who had no negative values recorded for non-renal clearance.

Between treatment comparison is shown in Figure 1.




Figure 1. Mean plasma dofetilide concentrations vs after three treatments on Day 11.

Table 3. Results of the statistical analysis of the PK data within treatment group (Day 4 vs Day 11).

<b>Within treatment results:</b>				
	Mean		Means Ratio <sup>(a)</sup> or Difference <sup>(b)</sup>	90% Confidence Interval
	Dofetilide + HCTZ			
	Day 4	Day 11		
AUC <sub>t</sub> (ng.h/ml)	16.6	21.0	1.26 <sup>(a)</sup>	(1.20, 1.33)
C <sub>max</sub> (ng/ml)	2.43	2.95	1.21 <sup>(a)</sup>	(1.10, 1.34)
T <sub>max</sub> (h)	1.78	2.63	0.84 <sup>(b)</sup>	(0.21, 1.48)
CL/f (ml/min)	511.0	403.9	-107.1 <sup>(b)</sup>	(-130.89, -83.36)
Ae <sub>t</sub> (mcg)	353.93	319.37	-35.34 <sup>(b)</sup>	(-82.64, 11.96)
CL <sub>R</sub> (ml/min)*	372.17	277.33	-96.45 <sup>(b)</sup>	(-146.20, -46.69)
CL <sub>NR</sub> /f (ml/min)*	158.50	148.42	-8.81 <sup>(b)</sup>	(-59.29, 41.67)

a = Means Ratio; b = Means Difference; \* n=2

	Mean		Means Ratio <sup>(a)</sup> or Difference <sup>(b)</sup>	90% Confidence Interval
	Dofetilide + HCTZ+ triamterene			
	Day 4	Day 11		
AUC <sub>t</sub> (ng.h/ml)	18.2	23.7	1.30 <sup>(a)</sup>	(1.24, 1.37)
C <sub>max</sub> (ng/ml)	2.83	3.29	1.16 <sup>(a)</sup>	(1.05, 1.29)
T <sub>max</sub> (h)	1.94	1.94	0.00 <sup>(b)</sup>	(-0.63, 0.63)
CL/f (ml/min)	462.3	356.9	-105.31 <sup>(b)</sup>	(-129.08, -81.55)
Ae <sub>t</sub> (mcg)	357.24	370.22	12.20 <sup>(b)</sup>	(-35.10, 59.50)
CL <sub>R</sub> (ml/min)	341.08	272.67	-70.03 <sup>(b)</sup>	(-119.79, -20.27)
CL <sub>NR</sub> /f (ml/min)	138.25	96.92	-40.06 <sup>(b)</sup>	(-90.54, 10.42)

a = Means Ratio; b = Means Difference

	Mean		Means Ratio <sup>(a)</sup> or Difference <sup>(b)</sup>	90% Confidence Interval
	Dofetilide + Placebo			
	Day 4	Day 11		
AUC <sub>t</sub> (ng.h/ml)	15.8	17.4	1.10 <sup>(a)</sup>	(1.05, 1.16)
C <sub>max</sub> (ng/ml)	2.25	2.66	1.18 <sup>(a)</sup>	(1.07, 1.31)
T <sub>max</sub> (h)	2.22	1.75	-0.47 <sup>(b)</sup>	(-1.10, 0.17)
CL/f (ml/min)	540.4	488.4	-52.00 <sup>(b)</sup>	(-75.76, -28.24)
Ae <sub>t</sub> (mcg)	321.23	363.41	41.76 <sup>(b)</sup>	(-7.47, 90.99)
CL <sub>R</sub> (ml/min)	360.64	377.82	16.30 <sup>(b)</sup>	(-35.49, 68.09)
CL <sub>NR</sub> /f (ml/min)	205.64	135.73	-69.22 <sup>(b)</sup>	(-121.76, -16.67)

Table 4. Results of the statistical analysis of the PK data between treatment groups.

	Adjusted Means Ratio <sup>(a)</sup> or Difference <sup>(b)</sup>		Means Ratio <sup>(c)</sup> or Difference <sup>(d)</sup>	90% Confidence Interval
	Dofetilide + HCTZ	Dofetilide + Placebo		
AUC <sub>c</sub> (ng.h/ml)	1.26 <sup>(a)</sup>	1.10 <sup>(a)</sup>	1.14 <sup>(c)</sup>	(1.06, 1.23)
C <sub>max</sub> (ng/ml)	1.21 <sup>(a)</sup>	1.18 <sup>(a)</sup>	1.03 <sup>(c)</sup>	(0.89, 1.18)
T <sub>max</sub> (h)	0.84 <sup>(b)</sup>	-0.47 <sup>(b)</sup>	1.31 <sup>(d)</sup>	(0.42, 2.21)
CL/f (ml/min)	-107.13 <sup>(b)</sup>	-52.00 <sup>(b)</sup>	-55.13 <sup>(d)</sup>	(-88.73, -21.52)
Ae <sub>t</sub> (ml/min)	-35.34 <sup>(b)</sup>	41.76 <sup>(b)</sup>	-77.10 <sup>(d)</sup>	(-145.20, -9.01)
CL <sub>R</sub> (ml/min)	-96.45 <sup>(b)</sup>	16.30 <sup>(b)</sup>	-112.75 <sup>(d)</sup>	(-184.39, -41.11)
CL <sub>NR</sub> /f (ml/min)	-8.81 <sup>(b)</sup>	-69.22 <sup>(b)</sup>	60.40 <sup>(d)</sup>	(-12.28, 133.08)

	Dofetilide + HCTZ + Triamterene	Dofetilide + Placebo		
	AUC <sub>c</sub> (ng.h/ml)	1.30 <sup>(a)</sup>		
C <sub>max</sub> (ng.h)	1.16 <sup>(a)</sup>	1.18 <sup>(a)</sup>	0.98 <sup>(c)</sup>	(0.85, 1.13)
T <sub>max</sub> (h)	0.00 <sup>(b)</sup>	-0.47 <sup>(b)</sup>	0.47 <sup>(d)</sup>	(-0.43, 1.37)
CL/f (ml/min)	-105.31 <sup>(b)</sup>	-52.00 <sup>(b)</sup>	-53.31 <sup>(d)</sup>	(-86.92, -19.70)
Ae <sub>t</sub> (mcg)	12.20 <sup>(b)</sup>	41.76 <sup>(b)</sup>	-29.56 <sup>(d)</sup>	(-97.66, 38.53)
CL <sub>R</sub> (ml/min)	-70.03 <sup>(b)</sup>	16.30 <sup>(b)</sup>	-86.33 <sup>(d)</sup>	(-157.97, -14.69)
CL <sub>NR</sub> /f (ml/min)	-40.06 <sup>(b)</sup>	-69.22 <sup>(b)</sup>	29.15 <sup>(d)</sup>	(-43.53, 101.83)

Source: Table 5.2.1

a = Ratio of means; b = Difference between means; c = Ratio of treatment ratios : (dofetilide + HCTZ + triamterene) / (dofetilide + placebo); d = Difference between treatment differences: (dofetilide + HCTZ + triamterene) – (dofetilide + placebo)

Since previous studies showed that women cleared dofetilide by 12-18% slower than men, the influence of gender in this study was tested with ANOVA. The interaction term for treatment by gender was not statistically significant at the 10% level for any of the pharmacokinetic analyses and this term was dropped from the model.

Several subjects (b) (6) and (b) (6), Day 4 and (b) (6) and (b) (6) on Day 11) had negative values for renal clearance and were excluded from urinary pharmacokinetic analyses.

The exposure to dofetilide (measured by AUC<sub>t</sub> and C<sub>max</sub>) was significantly larger (p<0.01) in both groups with the combination treatments when compared to dofetilide alone. In patients receiving HCTZ alone, dofetilide AUC increased by 27% and C<sub>max</sub> by 21%. In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and C<sub>max</sub> by 16%. The clearance values decreased from Day 4 to 11 in all groups and differences were statistically significant (p<0.01). The differences in T<sub>max</sub> and renal clearance for dofetilide from Day 4 to Day 11 were statistically significant (p<0.05). Changes in renal clearance between Day 4 and 11 for all groups were not statistically significant.

The sponsor compared the pharmacokinetic parameters on Day 4 (only dofetilide) by gender and found that gender effect on AUC, CL/f and CL<sub>NR</sub>/f was not significant in this study. Creatinine clearance and weight were statistically significant when added as

covariates to the analysis of the following pharmacokinetic parameters: AUC, CL/f and CL<sub>NR</sub>/f.

Table 5. Comparison of Pharmacokinetic Parameters by Gender (Day 4)

Parameter	Covariate	Ratio Males/Females	90% CI	Significance of Covariate (p-value)
AUCt	none	1.02	(0.93, 1.13)	-
	CLcr	1.15	(1.04, 1.26)	0.0001
	BWT	1.23	(1.06, 1.42)	0.0105
Cmax	none	1.04	(0.93, 1.16)	-
	CLcr	1.15	(1.02, 1.29)	0.0059
	BWT	1.19	(0.99, 1.42)	0.1144
Difference Between Males and Females				
CL/f	none	-9.38	(- 60.38, 41.63)	-
	CLcr	-69.20	(-118.77, -19.63)	0.2777
	BWT	-104.71	((-181.55, -27.87)	0.0106
CL <sub>NR</sub> /f	none	-32.16	(-91.24, 26.93)	-
	CLcr	-70.99	(-136.93, -5.05)	0.0001
	BWT	-158.14	(-244.69, -71.59)	0.0034

**Pharmacodynamics**

The sponsor compared mean QTc interval changes vs time for three treatments on Day 11, Figure 2. The combination treatments showed a marked increase of the QTc interval with a maximum of 70 msec (dofetilide + HCTZ + triamterene) at 2 hours post-dose and with a maximum of 75 msec (dofetilide + HCTZ) at 3 hours post-dose. In the dofetilide group, the QTc interval increased by 30 msec.




Figure 2. Mean change in 3-lead QTc interval vs time for three treatments on Day 11.

On Day 11, the QTc interval increased over 500 msec in 5 subjects from the dofetilide + HCTZ + triamterene group, in 8 subjects from the dofetilide + HCTZ group and in 2 subjects from the dofetilide group (3-lead ECG).

Figures 3, 4 and 5 compare mean QTc changes from baseline vs dofetilide plasma concentrations on Day 11 and Day 4.




Figure 3. Mean changes in QTc vs dofetilide plasma concentrations on Day 4 and after dofetilide-HCTZ treatment on Day 11.




Figure 4. Mean changes in QTc vs dofetilide plasma concentrations on Day 4 and after dofetilide-HCTZ-triamterene treatment on Day 11.




Figure 5. Mean changes in QTc vs dofetilide plasma concentrations on Day 4 and after dofetilide-placebo treatment on Day 11.

These plots visualize the changes of the QTc intervals in subjects who received either HCTZ or HCTZ-triamterene with dofetilide. The QTc changes were linearly related to dofetilide plasma concentrations. The sponsor described the PK/PD relationship using linear regression. The slopes of the change in QTc vs dofetilide plasma concentration on Day 4 and Day 11 were compared using ANOVA. The slopes for each of the combination treatment did not differ from the dofetilide-placebo treatment (Day 11). The between treatment differences for each of the treatment (Day 4 vs Day 11) were not statistically significant. The difference in slopes between gender (males, 17.47, females, 26.73) was marginally significant ( $p=0.0603$ ).

The sponsor compared the areas under the QTc interval vs time curves (AUECt) and the maximum of QTc changes (Emax) for three treatments at Day 4 and Day 11 using ANOVA (95% CI were calculated) (Table 6). The differences between parameters (AUECt and Emax) calculated for both the combination treatments and dofetilide were statistically significant ( $p<0.001$ ). In patients receiving HCTZ alone, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase). In patients receiving HCTZ in combination with triamterene, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase).

When the PD parameters were compared on Day 4 vs Day 11 in the dofetilide group, the differences were not statistically significant.

Table 6. Comparison of PD parameters on Day 4 and Day 11 for three treatment groups.

Parameter	Treatment	Day 4	Day 11	p
AUECt (SD), msec.hr	Dofetilide	148(134)	174(164)	<0.001
	Dofetilide+HCTZ	189(194)	561(258)	
	Dofetilide+HCTZ +triamterene	179(133)	520(249)	
Emax (SD), msec	Dofetilide	44(17)	44(25)	<0.001
	Dofetilide+HCTZ	50(20)	98(42)	
	Dofetilide+HCTZ +triamterene	45(14)	83(45)	

The AUECt values for Day 4 and Day 11 in the placebo group are lower in this study than other recent studies (A 1151001 and A 1151005). Furthermore the Day 11 AUEC values in the HCTZ and the HCTZ plus triamterene groups are higher than those seen in recent studies and may account for the difference.

The sponsor compared the mean change in QTc interval vs time for female and male subjects, Day 4, Figure 2. The female subjects had larger (mean value 51.3 msec) increase of the QTc interval than males (mean value 41.7 msec). The difference between genders was marginal (p=0.0541, 95% CI -19.51, 0.18). The plot comparing the changes in QTc on Day 4 in males and females does not reflect the mean statistics shown in the data (Figure 6).




Figure 6. Mean changes in 3-lead QTc after three treatments on Day 4, male and female subjects.

**Influence of serum electrolytes (analysis of covariance):**

The sponsor analyzed the influence of the following covariates: serum sodium, potassium, calcium and magnesium on the PD parameters. Only serum potassium had a significant effect on both Emax (P=0.0136) and AUECt (p=0.0146). The mean serum potassium values over time are shown in Figure 6.




Figure 7. Mean serum potassium concentrations vs time by treatment.

The relationship between serum potassium and Emax and AUECt are shown graphically in Figures 7 and 8. Both Emax and AUECt increased as serum potassium levels decreased.




Figure 8. Changes in QTc vs serum potassium concentration.




Figure 9. Changes in AUECT vs serum potassium concentration.

**Within Treatment Results (adjusted for serum potassium):**

	Mean		Mean Difference	95% Confidence Interval
	Dofetilide + HCTZ			
	Day 4	Day 11		
AUEC <sub>T</sub> (msec.h)	236.9	469.8	232.93	(62.6, 403.3)
E <sub>max</sub> (msec)	60.3	78.7	18.4	(-14.9, 51.8)

	Mean		Mean Difference	95% Confidence Interval
	Dofetilide + HCTZ+ triamterene			
	Day 4	Day 11		
AUEC <sub>T</sub> (msec.h)	213.0	485.7	272.8	(161.3, 384.3)
E <sub>max</sub> (msec)	52.4	76.1	23.7	(1.9, 45.5)

	Mean		Mean Difference	95% Confidence Interval
	Dofetilide + Placebo			
	Day 4	Day 11		
AUEC <sub>T</sub> (msec.h)	173.6	194.1	20.5	(-64.3, 105.3)
E <sub>max</sub> (msec)	49.1	48.0	-1.1	(-17.7, 15.5)

The results of the statistical analysis of the pharmacodynamic data for the within and between treatment comparisons adjusted for serum potassium are summarized in the following tables:

<b>Between Treatment Results (adjusted for serum potassium):</b>					
	Mean Difference		Difference between treatments	95% Confidence Interval	p-value
	Dofetilide + HCTZ	Dofetilide + Placebo			
AUEC <sub>t</sub> (msec.h)	232.9	20.5	212.4	(26.5, 398.4)	0.0262
E <sub>max</sub> (msec)	18.4	-1.1	19.5	(-16.9, 55.9)	0.2858

	Mean Difference		Difference between treatments	95% Confidence Interval	p-value
	Dofetilide + HCTZ + triamterene	Dofetilide + Placebo			
AUEC <sub>t</sub> (msec.h)	272.8	20.5	252.3	(115.1, 389.5)	<0.001
E <sub>max</sub> (msec)	23.7	-1.1	24.8	(-2.07, 51.7)	0.0695

The differences between treatments in AUEC<sub>t</sub> and E<sub>max</sub> were reduced when adjusted for the observed changes in serum potassium. The mean differences in AUEC between the dofetilide + HCTZ and dofetilide + placebo groups (212.4msec.h, 95% CI (36.5, 398.4) and between the dofetilide + HCTZ + triamterene and dofetilide + placebo groups (252.3msec.h, 95% CI: 115.1, 389.5) remained statistically significant. These differences were not statistically significant for E<sub>max</sub>.

The following table presents the changes observed in serum potassium levels between Day 4 and Day 11. The AUEC, and E<sub>max</sub> values presented are the predicted differences (Day 11 -Day 4) based on the observed changes in serum potassium.

<b>Changes observed in serum potassium levels and influence on pharmacodynamic results</b>		
Parameter	Arithmetic Means	
	Dofetilide + HCTZ	Dofetilide + HCTZ + Triamterene
	Day 11 - Day 4 <sup>o</sup>	Day 11 - Day 4 <sup>o</sup>
Serum potassium (meq/l)	-0.8	-0.4
AUEC <sub>t</sub> (msec.h) <sup>o</sup>	181.0	89.0
E <sub>max</sub> (msec) <sup>o</sup>	34.8	17.1

## Sponsor's Conclusions

Both the dofetilide + HCTZ group and the dofetilide + HCTZ + triamterene group had greater mean differences in QTc from Day 4 to Day 11 in AUECt and Emax compared with the mean difference observed in the dofetilide + placebo group. There was no statistically significant difference between genders for either parameter.

The serum potassium was lower in the two diuretic groups compared with the control and additional exploratory analyses were performed to assess the impact of this on QTc. These analyses indicated a consistent statistically significant effect of serum potassium for both Emax ( $p=0.0136$ ) and AUECt ( $p=0.0146$ ), which increased as serum potassium levels decreased. Using a linear model to relate the effect of serum potassium and dofetilide plasma concentrations on QTc allowed quantification of the effect. In the dofetilide + HCTZ group, 34.8msec of the observed increase in QTc of 47.6msec (73%) could be explained by the drop in serum potassium of 0.8meq/L and 10.76msec could be explained by the increase in Cmax. In the dofetilide + HCTZ + triamterene group, 17.1 msec of the observed increase in QTc of 38.1 msec (45%) could be explained by the drop in serum potassium of 0.4meq/l and 7.37msec could be explained by the increase in Cmax.

There was no significant difference in slope between Days 4 and 11 for any of the treatment groups and there were no differences between dofetilide + HCTZ or dofetilide + HCTZ + triamterene compared to dofetilide + placebo when considering the change in slope from Day 4 to Day 11. On Day 4, males had a mean slope of 17.4 7msec/ng/ml compared with the females who had a mean slope of 26.73msec/ng/ml but there was no evidence of a significant interaction between gender and treatment group.

Coadministration of dofetilide with HCTZ and with HCTZ and triamterene has shown a 14 to 18% effect on the AUC of dofetilide but no effect on Cmax. Coadministration of dofetilide with HCTZ and with HCTZ and triamterene has an effect on QTc increase of dofetilide, which is correlated to changes in serum potassium.

## COMMENTS:

1. For both combination treatments, dofetilide and HCTZ, and dofetilide, triamterene, and HCTZ, AUC<sub>t</sub> and CL/f values were statistically different from the treatment with dofetilide and placebo ( $p < 0.01$ ). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and C<sub>max</sub> by 21%. In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and C<sub>max</sub> by 16%. Additionally, T<sub>max</sub> and CL<sub>r</sub> for dofetilide and HCTZ treatment vs dofetilide and placebo treatment and CL<sub>r</sub> for dofetilide, triamterene, and HCTZ treatment vs dofetilide and placebo treatment differ significantly ( $p < 0.05$ ).
2. As it was shown previously, females had lower dofetilide plasma concentrations (smaller AUC and C<sub>max</sub>) and faster clearance than in males. Creatinine clearance and body weight were the statistically significant covariates ( $p < 0.01$ ) comparing gender for AUC<sub>t</sub>, CL/f, and CL<sub>NR</sub>/f. However, test for treatment by gender interaction did not show any significant gender influence in this study.
3. In Tables 5.1.1 – 5.1.3 the sponsor displayed the pharmacokinetic parameters calculated for the individual patients, and the values of their mean, standard deviation coefficient of variation, difference between day 11 and day 4, and ratio between day 11 and day 4 for each treatment group. The descriptive statistics of these parameters are summarized in Table 5.2.1. None of the descriptive statistics values for AUC, C<sub>max</sub>, T<sub>max</sub>, and CL/f shown in Tables 5.1.1 – 5.1.3 are the same as in Table 5.2.1 (the values from the later Table are included in the study report). The sponsor did not attempt to explain the discrepancy in the results in these two tables.
4. In this study, dofetilide administration for 11 days QTc prolongation was 2 fold higher in comparison with the previously available data (PI). The sponsor did not explain this discrepancy. Between gender comparison on Day 4 of receiving dofetilide revealed a marginal differences ( $p=0.0541$ ) between two groups.

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Elena Mishina  
9/15/04 03:30:49 PM  
BIOPHARMACEUTICS

Patrick Marroum  
9/15/04 03:47:02 PM  
BIOPHARMACEUTICS

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**020931Orig1s001**

**OTHER REVIEW(S)**

## RHPM Review of Draft Labeling

Application: NDA 20-931/S-001  
Tikosyn (dofetilide) 0.125, 0.25 and 0.5 mg Capsules.

Applicant: Pfizer

Document Date: March 19, 2004 (received March 22, 2004)

Submission Type: Changes Being Effected

### Background:

This supplement was submitted to update the labeling with new information regarding the interaction between dofetilide and hydrochlorothiazide. Additional minor changes have also been made and are noted below.

### Review:

1. Throughout, “TIKOSYN<sup>TM</sup>” has been changed to “Tikosyn<sup>®</sup>.”
2. Under **CONTRAINDICATIONS**, the following paragraph has been added after the second paragraph:

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with TIKOSYN is contraindicated (see **PRECAUTIONS, Drug-Drug Interactions**) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation.

3. The following sub-section has been moved from the **PRECAUTIONS** section to the **WARNINGS** section:

#### **Hypokalemia and Potassium-Depleting Diuretics**

Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics, increasing the potential for torsade de pointes. Potassium levels should be within the normal range prior to administration of TIKOSYN and maintained in the normal range during administration of TIKOSYN. (see **DOSAGE AND ADMINISTRATION**)

4. Under **WARNINGS/Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents**, the second sentence has been changed from:

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, and certain oral macrolides.

To:

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones.

5. Under **PRECAUTIONS/Information for Patients/**Medications and Supplements, the first sentence has been changed from:

Assessment of patients' medication history should include all over-the-counter, prescription and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see **CONTRAINDICATIONS**), trimethoprim alone or in combination with sulfamethoxazole (see **CONTRAINDICATIONS**), prochlorperazine (see **CONTRAINDICATIONS**), megestrol (see **CONTRAINDICATIONS**), ketoconazole (see **CONTRAINDICATIONS**), other cardiovascular drugs (especially verapamil - see **CONTRAINDICATIONS**), phenothiazines, and tricyclic antidepressants (see **WARNINGS**).

To:

Assessment of patients' medication history should include all over-the-counter, prescription and herbal/natural preparations with emphasis on preparations that may affect the pharmacokinetics of TIKOSYN such as cimetidine (see **CONTRAINDICATIONS**), trimethoprim alone or in combination with sulfamethoxazole (see **WARNINGS, CONTRAINDICATIONS**), prochlorperazine (see **WARNINGS, CONTRAINDICATIONS**), megestrol (see **WARNINGS, CONTRAINDICATIONS**), ketoconazole (see **WARNINGS, CONTRAINDICATIONS**), hydrochlorothiazide (alone or in combinations such as with triamterene) (see **CONTRAINDICATIONS**), other cardiovascular drugs (especially verapamil - see **CONTRAINDICATIONS**), phenothiazines, and tricyclic antidepressants (see **WARNINGS**).

6. Under **PRECAUTIONS/Drug-Drug Interactions**, “**WARNINGS**” has been added to the first parenthetical of the first sentence in the Cimetidine, Ketoconazole and Trimethoprim Alone or in Combination with Sulfamethoxazole sub-sections.

7. The following has been added to the **PRECAUTIONS/Drug-Drug Interactions** section:

Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: (see **CONTRAINDICATIONS**) Concomitant use of HCTZ alone or in combination with triamterene is contraindicated. HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose). In patients receiving HCTZ alone, dofetilide AUC increased by 27% and  $C_{max}$  by 21%. However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase). In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and  $C_{max}$  by 16%. However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase). The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium. In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).

8. Under **DOSAGE AND ADMINISTRATION**, the following has been added as the third bullet point:

Serum potassium should be maintained within the normal range before TIKOSYN treatment is initiated and should be maintained within the normal range while the patient remains on TIKOSYN therapy. (See **WARNINGS, Hypokalemia and Potassium Depleting Diuretics**) In clinical trials potassium levels were generally maintained above 3.6-4.0 mEq/L.

9. Under **DOSAGE AND ADMINISTRATION/Initiation of TIKOSYN Therapy/Step 2**, the term “body weight” has been changed to “actual body weight” in both creatinine clearance formulas (male and female).
10. The list number and issue date of the package insert have been updated.
11. In the Patient Information leaflet, under **Who should not take Tikosyn/Do not take Tikosyn if you/are taking certain other medicines, including, the following has been added:**  
  
Hydrochlorothiazide alone or in combination with other medicines (such as ESIDRIX, EZIDE, HYDRODIURIL, HYDRO-PAR, MICROZIDE, or ORETIC)\*
12. In the Patient Information leaflet, under **Important points about Tikosyn**, the following has been added to the end of the sixth bullet point:  
  
..., or hydrochlorothiazide alone or in combination with other medicines (such as ESIDRIX, EZIDE, HYDRODIURIL, HYDRO-PAR, MICROZIDE, or ORETIC)\*

**Comments/Recommendations:**

Dr. Mishina has reviewed this supplement. The Office of Clinical Pharmacology and Biopharmaceutics recommends approval of this supplement.

The labeling has been reviewed in a line-by-line comparison to the previously approved labeling and found to contain no other changes.

An approval letter will be drafted for Dr. Stockbridge’s signature.

---

Russell Fortney  
Regulatory Health Project Manager

rf/9/17/04

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Russell Fortney  
10/25/04 11:21:18 AM  
CSO

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**020931Orig1s001**

**ADMINISTRATIVE AND CORRESPONDENCE**  
**DOCUMENTS**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 20-931/S-001

Pfizer Inc  
Attention: Mr. Robert Clark  
235 E. 42<sup>nd</sup> Street  
New York, NY 10017

Dear Mr. Clark:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Tikosyn® (dofetilide) 0.125, 0.25, and 0.5 mg Capsules

NDA Number: 20-931

Supplement number: 001

Date of supplement: March 19, 2004

Date of receipt: March 22, 2004

This supplemental application, submitted as "Supplement - Changes Being Effected," proposes to update the professional and patient labeling with potential drug interaction information.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on May 21, 2004, in accordance with 21 CFR 314.101(a).

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Cardio-Renal Drug Products, HFD-110  
Attention: Division Document Room, 5002  
5600 Fishers Lane  
Rockville, Maryland 20857

Courier/Overnight Mail:  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Cardio-Renal Drug Products, HFD-110  
Attention: Division Document Room, 5002  
1451 Rockville Pike  
Rockville, Maryland 20852

If you have any questions, please call:

Mr. Russell Fortney  
Regulatory Health Project Manager  
(301) 594-5311

Sincerely,

*{See appended electronic signature page}*

Zelda McDonald  
Chief, Project Management Staff  
Division of Cardio-Renal Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Zelda McDonald  
3/26/04 11:03:34 AM